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A estrutura nativa das proteínas, decorrente do folding proteico, constitui um 
pré-requisito para a sua funcionalidade. No entanto, vários fatores promovem o 
folding incorreto (misfolding) de proteínas, causando a sua agregação. 
Recentemente, o misfolding e a agregação de proteínas têm sido associados 
às doenças cardiovasculares, que representam a principal causa de morte em 
todo o mundo. De forma a impedir a formação de agregados proteicos 
potencialmente tóxicos, os cardiomiócitos desenvolveram sistemas de controlo 
de qualidade proteica. Contudo, o seu comprometimento potencia a 
acumulação de proteínas disfuncionais na forma de agregados. Neste 
contexto, e tendo em consideração o papel do envelhecimento e da 
doxorrubicina (Doxo) no aumento do risco para o desenvolvimento de doenças 
cardiovasculares, será importante esclarecer a associação entre cada um 
destes fatores de risco e a agregação proteica. Deste modo, procuramos 
otimizar uma metodologia de enriquecimento de agregados proteicos 
provenientes de ventrículo esquerdo (VE) de um modelo animal de 
envelhecimento e de um modelo animal de cardiotoxicidade induzida pela 
Doxo, visando identificar as proteínas presentes nestes agregados por GeLC-
MS/MS. A técnica de isolamento de frações enriquecidas em agregados 
proteicos foi otimizada com sucesso em ambos os modelos animais. A análise 
por GeLC-MS/MS permitiu a identificação de 1279 e 1260 proteínas no VE de 
ratos WKY novos e velhos, respetivamente. A análise diferencial revelou que 
15 e 18 proteínas apresentavam níveis mais elevados nos agregados do grupo 
novos e velhos, respetivamente. Entre as proteínas presentes em maior 
quantidade nos ratos envelhecidos destacam-se aquelas relacionadas com a 
contração cardíaca (miosina-6 e miosina-7), o folding mediado pelas 
chaperonas (TRiC) e sistemas proteolíticos (catepsina D). Em relação ao 
modelo animal de cardiotoxicidade, 274 proteínas foram identificadas no grupo 
controlo e 267 no grupo Doxo. A análise diferencial revelou que apenas uma 
proteína, a glicoproteína rica em histidina (fragmento), apresentava níveis mais 
elevados nos agregados de animais tratados com Doxo. Esta proteína está 
envolvida na regulação de vários processos biológicos, como a inflamação e a 
angiogénese, sugerindo um possível papel da mesma na cardiotoxicidade 
induzida pela Doxo. A identificação destas proteínas bem como o 
conhecimento da sua relevância biológica fornece informações valiosas sobre 
o comprometimento da homeostasia das proteínas, tanto no envelhecimento 
como em condições de cardiotoxicidade. Desta forma, estudos futuros serão 
necessários para elucidar sobre o impacto real da agregação destas proteínas 
no envelhecimento cardíaco e em condições de cardiotoxicidade, bem como 
potenciais alvos terapêuticos. 
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abstract 
 
Native structure of proteins, acquired by protein folding, is required for them to 
function properly. However, several factors promote incorrect protein folding 
(misfolding), causing their aggregation. Recently, protein misfolding and 
aggregation have been associated with cardiovascular diseases, the leading 
cause of death worldwide. In order to avoid the generation of potentially toxic 
protein aggregates, cardiomyocytes have developed protein quality control 
systems. However, failure of these systems promotes the accumulation of 
abnormal protein aggregates. In this context, and taking into account the 
burden of aging and doxorubicin (Doxo) for cardiovascular diseases 
progression, it will be important to clarify the association between these two risk 
factors and protein aggregation. Therefore, we aimed to optimize the 
methodology for protein aggregates enrichment from left ventricle (LV) of aging 
and Doxo-induced cardiotoxicity animal models, and also to identify the 
proteins presented in these aggregates by GeLC-MS/MS. In both animal 
models, the technique for isolation of protein aggregates-enriched fractions was 
successfully optimized. GeLC-MS/MS analysis allowed the identification of 
1279 and 1260 proteins in young and aged WKY LV, respectively. Differential 
protein analysis revealed that 15 and 18 proteins were presented at higher 
amounts in young and aged groups, respectively. Among proteins with greater 
amounts in aged rats, we highlighted those related to cardiac contraction 
(myosin-6 and myosin-7), chaperone-mediated protein folding (TRiC) and 
proteolytic systems (cathepsin D). Regarding the animal model of 
cardiotoxicity, 274 proteins were identified in the control group and 267 in the 
Doxo group. Differential protein analysis revealed that only one protein, 
histidine-rich glycoprotein (fragment), was presented in higher amounts in 
aggregates from Doxo-treated animals. This protein is involved in the regulation 
of several biological processes, such as inflammation and angiogenesis, 
suggesting that it can play a role in Doxo-induced cardiotoxicity. The 
identification of these proteins as well as the knowledge of their biological 
relevance provides valuable information about protein homeostasis impairment, 
both in aging and in cardiotoxicity conditions. Therefore, future studies are 
necessary to elucidate the real impact of the aggregation of these proteins on 
cardiac aging and cardiotoxicity conditions, as well as potential therapeutic 
targets. 
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1. INTRODUCTION 
The process by which proteins acquire their native structure, named as folding, is crucial 
for proteins to perform their functions in cell and, consequently, essential to all biological 
processes. On the other hand, unfolding or incorrect folding (misfolding) of proteins and 
consequent loss of function may have catastrophic effects for cells functioning and trigger protein 
aggregation, which is per se toxic for the cell (1, 2). At the protein native structure, hydrophobic 
residues are mainly found in their core. However, when protein misfolds, a structural change 
exposes the hydrophobic residues, allowing them to interact in a non-specific way with other 
proteins causing abnormal protein aggregation (1). Moreover, it is known that excessive 
accumulation of misfolded proteins is related to the manifestation or progression of several 
cardiovascular diseases (2, 3). Therefore, the existence of protein quality control systems that 
ensure the correct synthesis and folding of proteins as well as the identification and repair or 
degradation of proteins with abnormal conformation are crucial for cells survival, namely 
cardiomyocytes (2). The systems responsible for protein quality control, which include chaperones 
and proteolytic systems, are essential for proteostasis, which means, the maintenance of proteome 
homeostasis. 
Chaperones are specialized proteins that interact, stabilize or assist other proteins to 
acquire their functionally active conformation, being absent in the final structure. Beyond 
participating in proteins folding, these molecules recognize and repair misfolded proteins, by 
binding to hydrophobic regions, thereby preventing aggregation. Additionally, chaperones are 
involved in protein transport, assembly of oligomeric proteins and proteolytic degradation (4). 
However, if chaperone activity becomes compromised, other systems will be initiated in order to 
restore proteostasis (2). Thus, sarcoplasmic reticulum (SR)-associated protein degradation, 
proteasomes, calpains system and lysosomal and mitochondrial proteolytic enzymes will work 
together in recycling or removing protein aggregates at a cellular level (5). Between proteolytic 
systems, ubiquitin-proteasome system (UPS) and autophagy are the two main pathways for protein 
degradation. 
UPS represent the second line of defense, being responsible for the degradation of 
misfolded, mutated or any other damaged soluble proteins. Moreover, UPS is responsible for the 
degradation of normal proteins that are no longer needed by the cells, contributing to the temporal 
regulation of protein activity. This process involves two main steps: protein ubiquitination and the 
subsequent degradation mediated by proteasomes. Ubiquitination consists in a post-translational 
modification in which the binding of a polyubiquitin chain to the target protein occurs through a 
cascade of enzymatic reactions, promoting its subsequent degradation by the proteasome (6). 
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 Lastly, autophagy allows degradation of dysfunctional organelles, misfolded proteins and 
protein aggregates (7). Autophagy, more specifically macroautophagy, involves the formation of a 
double-membrane vesicle around the substrates and its subsequent degradation through lysosomes 
(8, 9). Thus, chaperones and proteolytic systems ensure an optimal proteostasis and an adequate 
function of cardiomyocytes, both under physiological and stress conditions.  
However, when protein quality control systems are compromised, pathological conditions 
associated with protein misfolding and aggregation become evident. In fact, abnormal intracellular 
or extracellular accumulation of protein aggregates has been associated with the pathogenesis of 
several neurodegenerative diseases, such as Alzheimer’s, Huntington’s and Parkinson’s disease (1). 
The toxicity of these aggregates has been attributed to diverse factors, such as oxidative stress and 
mitochondrial dysfunction (10), proteasome inhibition (11) and autophagy impairment (12). 
Similarly, recent evidence suggests the presence of protein aggregates in cardiovascular diseases 
(3, 7), the leading cause of death in Europe, representing an important public health problem 
nowadays. It is estimated that more than 4 million of people die each year due to cardiovascular 
diseases. There are several risk factors associated with the development of cardiovascular diseases, 
including hypertension, obesity, aging, antineoplastic agents, among others (13, 14). 
Indeed, aging associates to the rising of cardiovascular diseases prevalence, aggravated by 
the ageing of the population, mostly ascribed to the improvement of medical treatments and 
consequent increase in the average of life expectancy (15). As part of aging process several 
changes in cardiac structure and function take place, such is the case of: 1) increased formation of 
reactive oxygen species (ROS) and oxidative stress; 2) progressive accumulation of damages in 
deoxyribonucleic acid (DNA), in ribonucleic acid (RNA), in lipids and in proteins (16, 17); 3) 
aggregation of proteins (18); 4) impaired metabolism; 5) changes in calcium (Ca
2+
) homeostasis 
(17); 6) cardiac fibrosis; 7) mitochondrial dysfunction; modifications in UPS and autophagy, 
mitophagy and apoptosis processes (16, 19), and 9) decreased number of cardiomyocytes 
compensated by hypertrophy of the remaining cardiomyocytes (20). 
Oncological diseases are the second cause of death worldwide. Nowadays, there are 
different radioactive and chemical treatments aiming to eliminate tumor cells. Over the last few 
years, enhancement in antineoplastic therapies has contributed to a significant improvement in the 
prognosis of oncological patients and also to a reduction in mortality of this population (13). 
Doxorubicin (Doxo), a member of the anthracycline family, is widely used in the treatment of 
several types of cancers, including leukemia, lymphoma and breast cancer. Besides Doxo 
effectiveness in tumor treatment, this chemotherapy drug is known to induce cardiovascular side-
effects, such as arrhythmia, cardiomyopathy and heart failure (HF), therefore limiting its clinical 
use (21-23). These cardiotoxic effects are usually progressive and irreversible, causing a negative 
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impact both in success of oncological treatment and in the life quality of patients (13, 23). At the 
molecular level, there are many mechanisms proposed to explain Doxo-induced cardiotoxicity, 
despite not been fully understood. Among the proposed mechanisms it is important to highlight the 
changes in mitochondrial function, ROS and oxidative stress increase, dysregulation of Ca
2+
 
handling, myofibrillar degradation, DNA damage as well as UPS and autophagy dysfunction and 
apoptosis (23-26). 
For all these reasons, this thesis aims to address the role of protein quality control systems 
in cardiac tissue, as well as the consequences of its dysregulation in the formation of protein 
aggregates. At the same time, it will also provide a general perspective of the impact of aging and 
Doxo in proteostasis dysregulation and protein aggregation associated to the progression of 
cardiovascular diseases. 
 
1.1 Protein misfolding and aggregation 
It is known that partially folded or misfolded proteins are prone to aggregation. Protein 
aggregates can adopt distinct structural organizations, such as soluble oligomers, amorphous 
aggregates, amyloid fibrils, inclusion bodies and aggresomes (4, 27, 28). With regard to the soluble 
oligomers, small aggregates composed by approximately 3-50 monomers (29), they represent 
intermediate species that can give rise to amorphous aggregates or amyloid fibrils (27). The way 
how aggregation goes depends on several factors such as temperature, pH (28) and peptide 
concentration (30).  
Amyloid fibrils consist in very well organized β-sheet conformation structures. These 
insoluble aggregates are rigid, unbranched and deposited in the extracellular or intracellular 
medium. Up to now, several amyloidogenic proteins were identified, being the main feature of 
these proteins their structural instability, which can be induced by mutations, post-translational 
modifications or specific medium conditions (such as pH and temperature) (31). Furthermore, 
formation of these structures occurs in several organs, namely in the heart, which may lead to the 
development of many cardiac diseases, such as HF (32). 
Additionally, the formation of larger protein aggregates, termed inclusion bodies, can 
occur. These structures resulted from coalescence of individual aggregates into a single one, and 
can contain amorphous aggregates and amyloid fibrils. Inclusion bodies can be transported along 
microtubules to a perinuclear region, where they form a structure denominated aggresome (27). 
Aggresome formation is thought to represent a cellular protective mechanism, because it allows the 
sequestration of misfolded proteins and aggregates in a single site, helping their subsequent 
removal by autophagy (29). However, it remains unclear which are the toxic species to the cells. In 
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fact, some studies demonstrate that soluble and smaller intermediate species, such as pre-amyloid 
oligomers, represent the major toxic threat for cells in detriment of larger aggregates, being the 
latter poorly correlated with the severity of clinical manifestation, for example the Alzheimer’s 
disease (27, 33). 
There are many internal and external conditions that contribute to protein aggregation, 
namely mutations, environmental stress factors such as temperature, aging and oxidative stress 
(34). The role of post-translational modifications, which can occur as a consequence of the above-
mentioned conditions, on protein aggregates formation has been increasingly recognized (5). For 
instance, when amino acids like proline, arginine, threonine or lysine are exposed to high levels of 
ROS, they became more susceptible to carbonylation. In turn, protein carbonylation is associated 
with loss of enzymatic activity, loss of ligand binding properties, increased susceptibility to 
proteolytic activity, aggregation and modification in transcriptional activities (35-37). Post-
translational modifications are not only involved in the formation of protein aggregates but also in 
dysregulation of proteolytic system components. In fact, excessive levels of ROS, like hydrogen 
peroxide (H2O2) and lipid peroxides, can inhibit or change many proteasome subunits, thereby 
compromising protein degradation and promoting aggregation of misfolded protein (5, 38, 39). 
 
 
1.2 Protein quality control systems 
1.2.1 Chaperones 
Heart is constantly under stress, even under physiological conditions, thereby requiring a 
continuous recycling and maintenance of proteins in order to work properly (2). For this reason, 
cardiomyocytes have developed quality control systems to establish a perfect balance between 
protein synthesis and degradation. In first place, chaperones play a crucial role in protein 
homeostasis (40), being present in cytosol, nucleus, mitochondria and SR of cardiomyocyte (41). 
Besides their participation in protein folding, chaperones regulate protein synthesis, transport, 
aggregation, disaggregation and degradation (4). They are also involved in intracellular signaling, 
controlling the conformational changes necessary to activation or deactivation of signaling 
mediators and their binding to signalosomes (42), a complex intracellular network composed of 
several components of different signaling pathways (43). 
Chaperones are proteins constitutively expressed in cardiomyocytes. Nevertheless, their 
expression increases under stress conditions in order to maintain protein homeostasis and prevent 
protein aggregates formation. Insoluble aggregates of non-sarcomeric or sarcomeric misfolded 
proteins are toxic to the cardiac cell, and may even trigger apoptosis. Increased chaperones 
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expression has as main goal to avoid accumulation of these misfolded proteins, by promoting their 
refolding or directing them to be degraded by UPS or autophagy (40). 
The chaperone machinery is composed by numerous proteins that cooperate with each 
other, and are typically known as stress proteins or heat shock proteins (HSP), once its expression 
is increased under stress conditions. In cardiomyocytes, they are usually divided into three main 
classes: the general chaperones (HSP70 and HSP90), the small heat shock proteins (sHSP) and the 
SR chaperones (40). Proteins that belong to HSP70 and HSP90 class, which have an ATPase 
domain, recognize and bind to exposed hydrophobic regions of the non-native conformation 
proteins, promoting their folding or refolding through several cycles of ATP binding and hydrolysis 
(4).  HSP70 and HSP90 interact with other proteins, the co-chaperones, which support chaperones 
to perform their functions, including protein folding (44). For example, the HSP70 reaction cycle is 
controlled not only by co-chaperone HSP40 but also by nucleotide-exchange factors (NEF). The 
hydrolysis of ATP into ADP is strongly accelerated by HSP40, thereby triggering the binding 
between substrate and HSP70. Moreover, HSP40 is capable of directly binding to unfolded 
polypeptides and recruit HSP70. After ATP hydrolysis, the binding of NEF to HSP70 ATPase 
domain triggers the catalysis of ADP-ATP exchange, resulting in substrate release. Accordingly, 
the substrate release allows fast-folding molecules to hide hydrophobic residues, avoiding their 
aggregation (Figure 1). Proteins unable to acquire their native structure after HSP70 cycle, such as 
actin and tubulin, can be redirected to chaperonins (HSP60 class). Chaperonins exhibit a structure 
capable of attaching a single unfolded protein at a time, allowing more stable conditions for a 
proper protein folding (4, 45). Regarding HSP90, this chaperone has been associated with several 
important signaling pathways in eukaryotic cells, including cell cycle, telomere maintenance, 
apoptosis, mitotic signal transduction, vesicle-mediated transport, innate immunity and target 
protein degradation (4). The evolution and maintenance of these functional networks is thought to 
depend on the ability of HSP90 to attenuate the effects of structurally destabilizing mutations in the 
protein complexes, thereby allowing the appearance of new potentialities in protein. Essentially, 
HSP90 acts in structural maturation and conformational regulation of various signal-transduction 
molecules, such as kinases and steroid receptors (46), using, like other chaperones, other regulators 
and co-chaperones to perform these functions (4).   
The sHSP constitute a class of chaperones which have smaller molecular weights and 
function in an ATP-independent manner. sHSP binds to unfolded/misfolded proteins promoting 
their folding/refolding in an independent manner or transferring damaged protein to ATP-
dependent chaperones, enabling protein refolding or degradation (47). Mutations in sHSP genes 
can result in protein aggregates formation, namely aggresomes, as observed in desmin-related 
cardiomyopathy which is triggered by a mutation in sHSP α-β-crystallin (3).  
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SR is the main organelle where protein folding occurs, being associated with the presence 
of various chaperones, specifically glucose-regulated protein 78 (GRP78), that belongs to HSP70 
family. In fact, dysfunctional SR results in accumulation of misfolded or unfolded proteins. SR 
chaperones mainly interact with three protein complexes, the activating transcription factor 6 
(ATF6), the inositol-requiring enzyme-1 (IRE1) and the protein kinase RNA-like ER kinase 
(PERK), present in membrane of this organelle. Under normal conditions, GRP78 chaperone 
associates with these complexes, inhibiting their functions. However, under stress conditions, 
GRP78 binds to misfolded proteins and dissociates from these complexes, activating them. These 
protein complexes function as transmembrane sensors that are capable of detecting the 
accumulation of misfolded or unfolded proteins, and consequently promote an increase expression 
of chaperones present in this organelle, inhibiting protein synthesis and activating misfolded 
proteins degradation, in order to restore proteostasis (40, 48). 
 
Figure 1: The HSP70 chaperone cycle. General representation of the HSP70 reaction cycle, ATP-dependent, 
controlled by the HSP40 co-chaperone and nucleotide-exchange factors (NEF). 
Adapted from (4). 
 
1.2.2 Ubiquitin-proteasome system  
Proteasomal proteolytic pathway is responsible for 90% of intracellular proteins 
degradation in eukaryotic cells. Therefore, it ensures that not required, misfolded, oxidized and 
other type of damaged proteins do not accumulate in cells, avoiding their toxic effects. This system 
exists mainly in two forms, the ATP-ubiquitin independent (20S) and ATP-ubiquitin dependent 
(26S). The first form is mostly responsible for the degradation of oxidized proteins as resulting 
from oxidative stress, being this system ATP-ubiquitin independent. On the other hand, ATP-
ubiquitin dependent involves protein ubiquitination and its subsequent degradation by 26S 
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proteasome (49, 50) (Figure 2). Ubiquitination refers to the addition of ubiquitin molecules to a 
protein substrate through a cascade of enzymatic reactions. This process involves three steps: 1) the 
ubiquitin-activating enzyme (E1) covalently binds to ubiquitin in an ATP-dependent manner, 
thereby resulting in its activation; 2) the ubiquitin-conjugating enzyme (E2) transfers ubiquitin 
molecule from the E1 to itself; 3) the ubiquitin ligase (E3) recognizes the specific protein substrate 
and transfers ubiquitin molecule from the E2 to a lysine residue present in substrate (Figure 2). The 
fate of ubiquitinated proteins depends on the length of the ubiquitin chain formed and on the 
specific sites of lysine residues in ubiquitin used for linkage. When substrates are tagged with four 
or more ubiquitin molecules (poly-ubiquitination), being attached to each other by their lysine 48, 
they become targeted for degradation by the 26S proteasome (2, 51). 
The 26S proteasome is a multicatalytic complex composed by two 19S regulatory subunits 
and a 20S proteolytic core. The 19S regulatory subunits, positioned at both ends of the 20S 
proteolytic core, have as main components chaperones, ATPases and enzymes that remove 
ubiquitin molecules from substrates (deubiquitinases). Hence, these subunits recognize poly-
ubiquitin chains formed in substrates, remove ubiquitin molecules from proteins, promote protein 
unfolding and its entry into the 20S proteolytic core, in an ATP-dependent manner (41). The 20S 
core has a cylindrical structure, being constituted by two β-rings and two external α-rings, 
containing each ring seven unique protein subunits. Three major types of peptidase activities have 
been identified in 20S proteolytic core: chymotrypsin-like, trypsin-like and caspase-like activities 
(also designated as peptidylglutamyl-peptide hydrolase), attributed to β5, β2 and β1 subunits, 
respectively. α-rings avoid the entry of non-specific substrates into the 20S proteolytic core, 
regulates the exit of peptides products from this core and can directly regulate the assembly and 
peptidase activities of β-rings (2) (Figure 2). Since UPS is responsible for the majority of protein 
degradation, loss of its activity may lead to accumulation of dysfunctional proteins and, 
consequently, cause dysfunction and cellular death. 
 
 
Figure 2: Ubiquitin-proteasome system (UPS). Proteins degradation by 26S proteasome involves the poly-
ubiquitination of substrates through a cascade of enzymatic reactions. E1-Ubiquitin-activating enzyme; E2-Ubiquitin-
conjugating enzyme; E3-Ubiquitin ligase. 
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1.2.3 Autophagy 
In eukaryotic cells, autophagy is the second protein degradation pathway, although it is the 
main cellular pathway responsible for degradation of long-lived proteins and unnecessary or 
dysfunctional organelles (9). This process is essential for degradation of proteins that deposit in 
larger aggregates, since they cannot be degraded by proteasome proteolytic cavity. Therefore, 
autophagy is crucial for cellular homeostasis maintenance, protecting cardiomyocytes function (7, 
52). There are three distinct forms of autophagy: macroautophagy, microautophagy and chaperone-
mediated autophagy. Macroautophagy is the most prevalent form of autophagy, so it is usually 
referred as autophagy. Macroautophagy begins with the formation of a double membrane, the 
phagophore, around cytoplasmic material and organelles. The fusion of the phagophore expanding 
ends originates a vacuole, called autophagosome. Then, autophagosome external membrane fuses 
with lysosome, forming the autolysosome. Subsequently, autolysosome content is degraded by 
lysosomal enzymes and the remaining components are released to the cytoplasm (53). The main 
difference between macroautophagy and microautophagy is that, in the latter, cytoplasmic content 
is directly incorporated into lysosomes through lysosomes membrane invaginations. Chaperone-
mediated autophagy consists in the recognition of cytosolic proteins by HSP70, which interact with 
lysosome-associated membrane protein type 2a (LAMP2A) receptor, present on lysosome 
membrane, allowing protein translocation into the lysosomes where they will be degraded (54, 55). 
Under basal conditions, autophagy activation occurs at low levels, but it can rapidly 
increase in response to various stimuli, such as starvation, thereby promoting cellular survival 
through the release of energetic substrates by degradation of cellular constituents (8, 9). Autophagy 
also seems to function in a selective manner in the elimination of dysfunctional organelles, protein 
aggregates and intracellular pathogens. Selective types of autophagy must ensure efficient 
recognition and sequestration of the specific substrates within autophagosomes. This process is 
mediated by proteins like p62 and neighbor of BRCA1 gene 1 (NBR1), which are capable of 
recognize ubiquitinated proteins in protein aggregates and connect them to the autophagic 
membranes (7, 56, 57). Nevertheless, excessive and uncontrolled autophagy activation may 
promote cellular death, through the destruction of proteins and organelles that are essential to the 
cells (9). Mitophagy is a particular case of selective autophagy responsible for the degradation of 
dysfunctional mitochondria. Dysfunctional mitochondria produce less ATP, generate increased 
amounts of ROS and are more prone to trigger apoptosis, thereby contributing to the development 
of HF (58, 59). In this context, the elimination of these damaged mitochondria, by mitophagy, is 
crucial for cardiomyocytes to work properly. Mitophagy is a rigorously controlled and very 
selective process that includes mitochondrial sequestration by autophagosome, which fuses with 
lysosome for posterior degradation (59). It has been described that PTEN-induced putative 
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kinase 1 (PINK1) and Parkin proteins play an important role in mitophagy regulation. Under 
healthy conditions, PINK1 is imported into mitochondria, through a process dependent of 
mitochondria membrane potential, being rapidly degraded and maintained at low levels. Upon loss 
of mitochondrial membrane potential, PINK1 accumulates on the mitochondrial surface, leading to 
the recruitment of E3 ubiquitin ligase Parkin, that ubiquitinates many mitochondrial outer 
membrane proteins. The ubiquitinated proteins serve as a signal for p62/SQSTM1 protein, which 
assists to the recruitment of autophagosome to mitochondria, thereby promoting mitophagy (59, 
60).  
Autophagy-related proteins (Atg), initially identified and characterized in yeast, are 
essential for the autophagic process since they are needed for the formation of autophagosome. 
After autophagy induction, these proteins associate following a hierarchical direction, to first 
mediate the phagophore formation and then its expansion into autophagosome (57). Autophagy is 
usually determined by microtubule-associated protein light chain 3 (LC3) protein levels. LC3 
protein consists in an autophagy marker which is involved in autophagosome formation. Briefly, 
LC3 protein is converted to its cytosolic form LC3-I, by Atg4 cysteine protease. Then, LC3-I is 
activated by Atg7, transferred to Atg3 and conjugated with phosphatidylethanolamine (PE), 
thereby converting in LC3-II, that is recruited to phagophore double membrane, forming the 
autophagossome. Therefore, the amount of LC3-II is associated with the number of 
autophagosomes (53, 55). There are many signaling pathways that play an important role in 
autophagy regulation, namely mammalian target of rapamycin (mTOR), phosphatidylinositol 3-
kinase-I/protein kinase B (PI3K-I/Akt), a AMP-activated protein kinase (AMPK) and mitogen-
activated protein kinase/extracellular signal-regulated kinase 1/2 (MAPK/Erk1/2) (54, 55), as 
described in Figure 3. 
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Figure 3: Autophagy regulation. The kinase mTOR is the main regulator of autophagy. mTOR activation 
promotes autophagy suppression, whereas mTOR inactivation promotes autophagy induction. mTOR can be 
positively regulated by PI3K-I/Akt and MAPK/Erk1/2 signaling pathways and negatively by AMPK and p53. 
mTOR regulates autophagy through several pathways, namely acting in ULK1 complex, in kinase p70S6 and in 
transcription factor TFEB. On the other hand, AMPK is also capable of regulating autophagy by acting directly in 
ULK1 complex and in beclin-1. Additionally, Bcl-2, an anti-apoptotic regulator, also regulates autophagy by beclin-
1 inhibition. AMPK- AMP activated protein kinase; PI3K-I/Akt- phosphatidylinositol 3-kinase/protein kinase B; 
MAPK/Erk1/2- mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2; mTOR- mammalian 
target of rapamycin; ULK1- UNC-51 like kinase 1; TFEB- transcription factor EB; P70S6K- Ribosomal Protein S6 
Kinase Beta-1; Bcl-2- B-cell lymphoma 2. 
 
 
In addition to UPS and autophagy, proteases also integrate the main proteolytic systems 
present in cardiomyocytes. Calpains are cytoplasmic Ca
2+
-dependent cysteine proteases which 
participate in several Ca
2+
-mediated intracellular processes. Although its physiological function has 
not yet been fully understood, it is known that calpains are involved in cell migration, apoptosis, 
autophagy and plasma membrane repair. Nevertheless, m-calpains and µ-calpains, expressed in 
cardiomyocytes, are responsible for degradation of myofibrillar proteins, particularly troponin, 
tropomyosin, myosin and titin (61). Suppression of calpain-1 activity, by overexpression of 
calpastatin (a specific endogenous inhibitor for calpain), resulted in development of dilated 
cardiomyopathy, which is accompanied by a decrease of ubiquitinated proteins, protein aggregates 
formation, increase in autophagy and destruction of sarcomeres integrity (62). So, calpain-1 
activity is essential in maintenance of cardiac function and regulation of specific sarcomeric 
proteins (62). Additionally, it is known that dystrophins are degraded by calpain. Degradation of 
dystrophins impairs the integrity of the sarcolemma, leading to cardiac dysfunction and HF. 
Therefore, calpain inhibition may be a therapeutic target in the regulation of dystrophin 
degradation, delaying the progress to HF (61). 
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1.3 Dysregulation of proteostasis in aging 
Aging is characterized by progressive decline of cellular proteostasis, and consequently, by 
accumulation of misfolded and damaged proteins in different organs and tissues (63). In fact, it has 
been reported the accumulation of protein aggregates in the heart during its natural aging process. 
Ayyadevara et al. reported an aging-dependent increase of detergent-insoluble aggregates isolated 
from mice hearts (18). Since protein aggregation is suppressed by protein quality control systems, it 
becomes relevant to clarify how these systems change through aging and its implications on protein 
aggregates formation, and consequently on cardiac aging (Figure 4). Knowledge of the mechanisms 
that contribute to cardiovascular aging would have important clinical impact in cardiovascular 
disease prevention, early diagnosis and development of treatments (18).  
 
Figure 4: Overview of molecular changes during aging. Aging promotes among other, damage in DNA, RNA, lipids and 
proteins, changes in Ca2+ homeostasis, mitochondrial dysfunction, ROS and oxidative stress increase. Aging is also 
associated with dysregulation in protein quality control systems, namely, chaperones, UPS, autophagy and mitophagy. All 
these changes may lead to a disruption in protein homeostasis and, consequently, to the increase of protein aggregates 
formation. 
 
The induction of HSP synthesis, in response to stress factors, is crucial to maintain the 
proteostasis balance, preventing the formation of protein aggregates potentially toxic to 
cardiomyocytes (40). Nevertheless, different studies have shown that the induction of several 
chaperones in cardiac tissue from aged animals was compromised in response to various stress 
stimuli, such as temperature increase and physical exercise (64, 65). Thus, aging is associated with 
a decreased ability for chaperone synthesis, under stress conditions. Furthermore, Ayyadevara and 
colleagues found that HSP70, HSP90α and HSP90β levels were significantly diminished in 
aggregates from aged hearts, whereas HSP75, a mitochondrial HSP which protects against cardiac 
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hypertrophy and fibrosis, was absent (18). At the same time, the authors observed an increase of 
HSP70 in aggregates from young mice, highlighting its protective functions. Regarding sHSP 
(HSP-β6, HSP-β7 and HSP-β8), they were more abundant in aggregates from aged hearts. 
Moreover, tropomyosin levels were increased in aggregates of aged hearts, which can indicate that 
the rise in the sequestration of tropomyosin within aggregates may contribute to a decrease in 
cardiac contractility during aging (18).  
When protein function cannot be restored from misfolded proteins or aggregates, 
chaperones direct them to the proteolytic systems (Figure 4). The presence of ubiquitinated proteins 
in aggregates, a feature of different diseases, can be related to inefficient directing of proteins to 
proteasomes, resistance to degradation or UPS impairment, thereby contributing to the 
accumulation of these proteins (63). It has been reported that the activities of ubiquitinating 
enzymes E1, E2 and E3 did not show any consistent change with age, while the accumulation of 
ubiquitinated and oxidized proteins is evident both in aging and in diseases associated with aging 
(66). 
Dysfunction of UPS, namely proteasome activity in both hypertrophic cardiomyopathy and 
failing hearts has been reported, suggesting that proteasome functional insufficiency plays a major 
role in cardiac pathogenesis (39). The decrease of peptidase activity present in proteasome, namely 
the chymotrypsin-like activity (67), has been reported in aged tissues, specifically in cardiac tissue. 
Li et al. demonstrated that chymotrypsin-like activity of 20S proteasome was significantly reduced 
in the cardiac tissue of old rats (25 months) comparative to younger rats (3 months). The decline in 
20S proteasome function may be due, in part, to the decrease in the amount of β subunits observed 
in aged hearts, since these subunits are responsible for the peptidase activities of the proteasome. 
(68). Furthermore, aging also seems to influence other peptidase activities besides the 
chymotrypsin-like activity. So, analysis of 20S proteasome purified from rat’s hearts with different 
ages revealed a significantly decrease in peptidylglutamyl-peptide hydrolase and trypsin-like 
activities on aging, with a consequent reduction of the ability of the 20S proteasome to degrade 
protein substrates (69). These results suggest that a decrease in proteasome activity occurs during 
aging. 
When protein aggregation is not controlled by chaperone and proteasome activities, 
autophagy is promoted (5) (Figure 4). The effect of aging in cardiac autophagy has been reported in 
some studies, although the results revealed to be inconsistent. Taneike et al. found in homogenates 
from C57BI/6 mice hearts with 6, 14 or 26 months that LC3-II levels were lower comparing to the 
LC3-II levels present in mice with 10 weeks, suggesting that autophagy decreases with age (19). 
On the other hand, Inuzuka et al. observed that LC3-II levels remained constant in both young (3 
months) and old (20-24 months) rats, indicating that autophagy does not change during aging (70). 
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Wohlgemuth et al. studied the impact of aging in expression levels of proteins involved in the 
formation of autophagosome (beclin-1 and LC3-II) and in the degradation by autolysosomes and 
lysosomes (procathepsin D and LAMP-1). These authors observed an increase of beclin-1 and 
procathepsin D expression and a decrease of LAMP-1 expression in hearts from old rats (26 
months) comparing with young controls (6 months). In addition, they also verified that LC3-II 
protein expression was significantly increased in older rats (71). The differences in results between 
the studies could be due to experimental variables, such as animal model features. Besides, it is 
important to refer that these studies were based on determination of LC3-II levels, however, the 
increase in LC3-II does not always represent an induction of autophagy, but it can indicate either 
an increase in autophagosome formation or a blockade of autophagy pathway. In order to evaluate 
autophagy induction it is essential the determination of autophagic flux, since it is representative of 
the whole process, namely from the inclusion of substrate within the autophagosome, its delivery to 
lysosomes (through fusion of autophagosome with lysosome) and the release of the resulting 
degradation macromolecules into the cytoplasm (53). Therefore, more studies are needed to 
characterize autophagic flux changes in cardiomyocytes through aging.  
As mentioned before, aging is associated with the increase of dysfunctional mitochondria. 
Thus, the elimination of damaged mitochondria by mitophagy is important during aging. It has 
been described that the process of Parkin-mediated mitophagy is impaired in aged hearts (60). In 
fact, the deletion of Parkin promotes the accumulation of dysfunctional mitochondria in mice hearts 
with aging (72). Moreover, overexpression of this protein leads to an increase of mitophagy in aged 
cardiomyocytes, accompanied by a decrease of dysfunctional mitochondria and an improvement in 
cardiac function associated with aging. Therefore, the activation of mitophagy could be a novel 
target to attenuate the development of cardiovascular diseases induced by aging (60). 
Many studies also shown that changes in lifestyle can efficiently retard aging through 
improvement of autophagy. For instance, He et al. demonstrated that physical exercise increases 
heart autophagy (73) and has beneficial effects in prevention of both cardiovascular diseases and 
age-related diseases (74). Furthermore, caloric restriction is also a potent inducer of autophagy, 
with cardioprotective effects (71). Although physical exercise and caloric restriction manifest 
beneficial effects in aging prevention, pharmacological induction of autophagy is often used to 
prevent aging and several age-related diseases (54). Resveratrol has been investigated as a potential 
therapeutic strategy, although its beneficial effects in cardiomyocytes seem to be dose dependent. 
Therefore, it is essential to develop pharmacodynamics studies to better understand their 
cardioprotective or cardiotoxic effects (75). Rapamycin, an mTOR inhibitor, is also considered 
promising in aging treatment since it can provide functional benefits in aged hearts (76, 77). 
Wilkinson et al. have shown that rapamycin-treated rats presented a delay in the development of 
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many diseases associated to aging, including degenerative changes in myocardium. On the other 
hand, chronic treatment with this drug caused harmful side-effects that can impair functions in 
some tissues (77). In conclusion, there is still a long way to go to fully understand the role of 
protein aggregation in proteostasis deregulation induced by aging.  
 
1.4 Dysregulation of proteostasis caused by doxorubicin 
The pathophysiological mechanisms associated with Doxo-induced cardiotoxicity have not 
been fully elucidated. Nevertheless, previous studies have consistently reported the cumulative-
dose related cardiotoxic profile of Doxo, a feature that limits the extent to which it can be used 
safely. Moreover, its cardiotoxicity is also dependent of the administration schedule, the 
concomitant use of other cardiotoxic therapies, history of cardiac diseases, age and gender (13, 78). 
Anthracycline-induced cardiotoxicity presents both acute and chronic effects. Acute cardiotoxicity 
occurs during or immediately after Doxo treatment, being rare and not dose dependent (79). Doxo-
induced cardiotoxicity may become clinically evident later in the course of chemotherapy and 
within one year after therapy finalization (early-onset chronic cardiotoxicity), or more than one 
year after its completion (late-onset chronic cardiotoxicity) (13). In the latter, cardiac abnormalities 
are usually persistent and progressive, eventually triggering cardiac cells death (23, 78). This injury 
is typically characterized by the development of left ventricular systolic dysfunction, which 
subsequently progresses towards dilated cardiomyopathy and HF (23, 80).  
Over the last few years, it has been demonstrated that Doxo is able to induce changes in 
chaperones, UPS as well as in autophagy processes (Figure 5). The dysregulation of protein quality 
control can promote an increase in protein aggregates formation, which may induce toxic effects in 
cardiomyocytes. As mentioned above, evidences suggest a link between anthracycline-induced 
cardiotoxicity and changes in chaperone expression (22). For instance, cardiac biopsies from 
rabbits treated with other anthracycline, daunorubicin (3mg/kg, weekly, 10 weeks), showed an 
increase in the expression of various chaperones and proteins involved in chaperone-mediated 
autophagy, as well as an activation of proteolytic machinery (81). Moreover, Doxo-induced 
cardiotoxicity was also related to SR chaperones dysregulation/inhibition, such as GRP78 
chaperone. In fact, Fu et al. showed that Doxo induced an apoptotic response in cardiomyocytes, 
through the activation of ER mechanotransmembrane sensors, accompanied by the inhibition of 
GRP78 expression, which in turn potentiates the increase of ER stress (48).  
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Figure 5: Overview of molecular mechanisms in Doxo-induced cardiotoxicity. Doxo promotes among other, DNA 
damage, dysregulation of Ca2+ handling, myofibrillar degradation, mitochondrial dysfunction, ROS and oxidative 
stress increase. This drug is also capable to dysregulate protein quality control systems, namely, chaperones, UPS, 
autophagy, mitophagy and calpain. All these changes may lead to a disruption in protein homeostasis and, 
consequently, to the protein aggregates formation. 
 
 
For this reason, recently, chaperones have been intensively studied as potentially new 
therapeutic targets for cardiac diseases induced by antineoplastic agents. Based on experiments 
performed in Doxo-induced cardiotoxicity animal model, in which a decrease of HSP20 expression 
in cardiac tissue was observed, Fan et al. demonstrated that overexpressing this chaperone 
triggered an improvement in Doxo-induced deleterious effects, including higher resistance to 
apoptosis, enhanced cardiac function and increase animal survival after chronic Doxo treatment 
(82). These authors also showed that the mechanisms underlying these beneficial effects are 
associated with the preservation of Akt phosphorylation/activity, as well as the decrease in 
oxidative stress induced by Doxo (82, 83). 
The specific effects of Doxo in UPS have been already reported, although some results 
remain controversial. Briefly, when Doxo is administrated it diffuses through cellular membrane 
into the cytosol where it interacts with the proteasome. The complex formed is translocated to the 
nucleus, and there Doxo is released from proteasome which allows its binding to DNA (Figure 5) 
(84). Protein ubiquitination is generally a requirement for proteins to be degraded by the 26S 
proteasome, being that the specificity of ubiquitination resides mainly in ubiquitin ligase E3, as 
already mentioned (50, 51). In H9C2 cardiomyoblasts cell culture and in hearts from tumour-
bearing GFP-LC3 mouse model, the treatment with Doxo induced a significant increase of E3 
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ligases RING-finger protein-1 (MURF-1) and muscle atrophy F-box (MAFbx) expression, which 
tag by ubiquitination, myofibril proteins in skeletal and cardiac muscle. Moreover, protein 
ubiquitination was also significantly augmented both in vitro and in vivo models, with proteins 
tagged with poly-ubiquitin chains displaying the higher range of molecular weights and possibly 
indicating degradation of proteins involved in cardiac muscle structure, by the 26S proteasome 
(85). However, Doxo caused a significantly reduction on proteasome chymotrypsin-like activity, 
indicating that this drug is able to inhibit the proteasome (85). The mechanism by which Doxo 
alters proteasome activity appears to be regulated by the amount of Doxo molecules binding onto 
the proteasome (86), namely, proteasome activation at lower concentrations and its inhibition at 
higher Doxo concentrations (25, 87). 
Doxo is also capable of inducing post-translational modifications, such as carbonylation, in 
some sarcomeric proteins (Figure 5), thereby increasing the probability of these proteins to be 
degraded by proteasome. Recently, it was demonstrated in hypertensive rats that Doxo-induced 
oxidative stress induces high levels of carbonylation in sarcomeric proteins, more evidenced in 
myosin binding protein C (MyBPC). In addition, an increase in MyBPC degradation by proteasome 
was observed, resulting in a reduction of MyBPC levels in cardiomyocytes, as well as in 
impairment of the interaction of this protein with actin, thereby affecting cardiac cell contractility 
(88).  
With regard to Doxo effects on cardiac autophagy they are still controversial. For instance, 
a study demonstrated that Doxo promotes autophagic flux in cardiomyocytes. In fact, treatment 
with bafylomicin-A, a lysosomal H-ATPase inhibitor that impairs the fusion of autophagosome 
with lysosome, originated a significant increase in LC3-II levels in cardiomyocytes treated with 
Doxo compared with their controls. In addition, the increase in autophagy induced by Doxo 
potentiated cardiomyocytes death, suggesting that autophagy activation contributes to Doxo-
induced cardiotoxicity (89). In contrast, several studies appear to contradict these results by 
reporting that Doxo inhibits autophagic flux in cardiomyocytes rather than induces it (90, 91). This 
result can be explained by the effect of Doxo on the Akt/mTOR pathway activation which leads to 
suppression of autophagy. The significantly decrease in proteins involved in this process like 
beclin-1, LC3 and p62, after Doxo treatment, also corroborate this finding (91). Further, the block 
of autophagic flux in cardiomyocytes can be a consequence of Doxo’s capacity to inhibit lysosomal 
acidification, and consequently, lysosome function. In fact, neonatal rat cardiac myocytes treated 
with Doxo demonstrated an increase in lysosome pH from 4.6 to 5.2 thereby compromising 
lysosome hydrolases activities and proteolysis process. So, blocking the autophagic flux leads to 
autolysosome accumulation, promoting an increase of ROS, which contribute to Doxo-induced 
cardiotoxicity (90). Interestingly, the same authors showed that inhibition of the autophagic flux 
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induced by Doxo seems to be transitional (90). Also, it was demonstrated that Doxo is capable of 
impairing cardiac autophagy by suppressing TFEB expression, which regulates the transcription of 
genes related to autophagy and lysosomal biogenesis and function. In fact, the loss of TFEB in 
cardiomyocytes led to a reduction in macroautophagy protein expression, inhibition of autophagic 
flux, impairment in lysosomal cathepsin B activity and activation of cell death. Whereas TFEB 
overexpression in Doxo-treated cardiomyocytes augments lysosomal proteolysis, decreases ROS 
overload, attenuates cleaved caspase-3 expression and improves cardiomyocyte viability (92). 
Efficient and functional mitochondria networks are essential to myocardial contraction as 
well as for the cardiomyocytes survival. Doxo triggers a cellular cascade leading to mitochondria 
damage, that eventually culminates with cell death (Figure 5). Since mitochondrial density is 
greater than 35% in cardiomyocytes, Doxo-induced mitochondrial dysfunction may cause a severe 
lack of energy supply to these cells (93). A recent study, using in vitro and in vivo models, 
indicates that exposure to Doxo promotes a decrease in mitophagy mediated by Parkin protein. 
This reduction seems to be due to the interaction between cytosolic p53 protein and Parkin protein, 
which inhibits the translocation of the latter to the dysfunctional mitochondria. Thus, elimination of 
dysfunctional mitochondria by mitophagy seems to be compromised in cardiotoxicity, leading to 
cardiac dysfunction (60). However, in H9C2 cardiac myoblasts treated with Doxo, Weiner et al. 
reported an increase in mitochondrial fragmentation and in mitophagy. These results were 
accompanied by an increase of protein levels and mitochondrial translocation of Parkin and PINK1 
2 hours after Doxo treatment, however only PINK1 protein levels maintained higher during 24 
hours. Considering this, the same authors studied the effect of Parkin overexpresssion (via 
adenovirus), that accelerated Doxo-induced mitochondrial morphology changes and induced 
mitophagy, which in turn was associated with an increase in cell death. On the other hand, Parkin 
genes inhibition (via siRNA) prevented Doxo-induced mitophagy and diminished apoptosis 
markers levels (94). 
Regarding these evidences, Doxo has the ability to induce modifications in protein quality 
control systems, being associated with the formation of protein aggregates, which may contribute 
to the cardiotoxicity induced by this anthracycline. Since the existing information is still 
controversial, it is essential to carry out further studies in order to understand the role of Doxo in 
protein aggregates formation and its relationship with the cardiotoxicity. 
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1.5 Methodological approaches to study protein aggregates 
The characterization of protein aggregates can provide valuable insights into the 
understanding of cardiomyocytes’ remodeling in response to aging and mechanisms underlying 
cardiotoxicity. Several methodological approaches have been proposed. Bastos et al. (5) 
highlighted the potential of mass spectrometry (MS) for protein aggregation research once it allows 
protein identification and characterization from complex mixtures of biological origin. Protein 
aggregates are not homogeneous in regard to their size, composition and morphology. Such 
heterogeneity makes the study of protein aggregation challenging (95). The identification of 
aggregates components is troubled by difficulties in the isolation of protein aggregates, thereby no 
standard method was yet proposed. The generally approach for the isolation of proteins aggregates 
are based on the fact that insoluble aggregates, namely amyloids, are resistant to strong detergents. 
This property allows the isolation of amyloids by centrifugation in the presence of detergent (96). 
Different detergents have been proposed to isolate protein aggregates, such as sodium dodecyl 
sulphate (SDS) or sodium N-lauroylsarcosinate (sarcosyl) (18, 97). Some studies demonstrated that 
amyloids can be isolated from yeast cell lysates by sedimentation in the presence of SDS, showing 
the role of SDS in the isolation of protein aggregates (96). However, it has been reported that the 
use of a milder detergent, like sarcosyl, instead SDS that presents a strong denaturant effect and 
impairs protein’s native conformation, allowed the purification of amyloid aggregates which cannot 
withstand SDS treatment (97). Furthermore, in cardiac tissue, the use of sarcosyl, was also shown 
to be efficient in the isolation of protein aggregates-enriched fractions (18). Resolubilization of 
insoluble aggregates is a crucial step to ensure adequate separation of proteins in SDS 
polyacrylamide gel electrophoresis (SDS-PAGE). Due the high insolubility of protein aggregates, 
the use of high percentage of strong detergents to protein aggregates solubilization is essential to 
achieve maximal protein recovery (98). Gel electrophoresis is commonly used for estimating 
protein size, identifying proteins and determining sample purity (95). SDS-PAGE is a simple and 
very frequently used approach to separate and analyze the extracted protein aggregates (95). Also, 
this separation method allows downstream identification of proteins by MS after in-gel digestion. 
This method is preferable to the alternative in-solution digestion, because many MS interferents are 
trapped inside the gel, while peptides can be easily recovered from the polyacrylamide matrix (99, 
100). The study of protein aggregates is still a major challenge, taking into account that protein 
aggregation is a dynamic process that can be influenced by several factors, such as temperature, 
protein concentration and pH (95). Therefore, development/optimization of methods for isolation 
of the aggregates and identification of the associated proteins can be essential for understanding the 
cellular processes underlying the aggregation-driven toxicity. 
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2. AIMS 
The main objectives of the work carried out were to investigate the potential involvement 
of protein aggregation in the pathophysiological mechanisms underlying the cardiovascular 
changes associated with aging, as well as to understand the mechanisms by which the protein 
aggregation promotes Doxo-induced cardiotoxicity. For this purpose, the first goal was to optimize 
the methodology for protein aggregates enrichment isolated from left ventricle (LV) of an animal 
model of aging and an animal model of cardiotoxicity. Then, the second goal was to identify 
proteins from aggregates-enriched fractions by SDS-PAGE followed by liquid chromatography-
tandem mass spectrometry (GeLC-MS/MS). The last goal was to understand if the biological 
processes associated to the proteins present in aggregates differ between young and aged rats LV 
and between LV from healthy and Doxo-treated animals, as well as their biological implications. 
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3. MATERIALS AND METHODS 
3.1 Animal model  
 
3.1.1 Aging animal model: Left ventricular samples from a rat model of aging previously 
established in our laboratory were used for studying protein aggregation. Briefly, young and aged 
male Wistar Kyoto rats (WKY, n=5 each group) (Charles River, US) were maintained for 25 
weeks-old and 20 months-old, respectively, in individually ventilated chambers, in a controlled 
environment with a 12:12h light/dark cycle at 20 ± 2ºC room temperature. Water and standard diet 
were provided ad libitum.  
 
3.1.2 Doxo-induced cardiotoxicity model: Left ventricular samples from a rabbit model of 
cardiotoxicity previously established in our laboratory were used for studying protein aggregation. 
Briefly, a well-documented regimen was used for the induction of HF due to doxorubicin toxicity 
(101). Male New Zealand white rabbits (n=5) received a bolus of doxorubicin (Doxo group, 
1mg/Kg, iv) via marginal ear vein, twice a week for 8 weeks, followed by a washout period of 1 
week. Control rabbits (n=5) received 0.9% saline (vehicle) in equivolumetric doses over the same 
period. The animals were housed in stainless steel cages in a controlled environment with a 12:12h 
light/dark cycle at 20 ± 2ºC. Water and standard diet were provided ad libitum.  
 
At the end of the experiments, rats and rabbits were euthanized under anesthesia and 
subsequently LV were collected, snap frozen in liquid nitrogen and stored at -80ºC for protein 
aggregates studies. Experiments conformed to the Guide for the Care and Use of Laboratory 
Animals published by the National Institutes of Health (NIH Publication no. 85–23, revised 2011) 
and was approved by the ethics committee of the Faculty of Medicine of University of Porto.  
 
3.2 Baseline protocol for protein aggregates extraction and purification 
The methodological approach for the isolation of protein aggregates-enriched fractions was 
based on the Ayyadevara et al. protocol (18).  In order to optimize the technique, different 
conditions were tested: 1) tissue homogenization method (potter or beads); 2) DNase treatment; 3) 
protein precipitation method (TCA/acetone or acetone); 4) tissue amount; 5) sample type (failing 
and healthy myocardium); 6) different animal species (rat and rabbit). The optimized protocol is 
described in “Results” section. 
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3.3 In-gel protein digestion 
For protein identification by LC-MS/MS, several steps were performed. First, lanes of the 
12% SDS-PAGE gel were cut and sliced into 16 sections and each section was washed two times 
with 50 mM ammonium bicarbonate (NH4HCO3) for 30 minutes and acetonitrile (ACN) for 30 
minutes each, to remove the staining and contaminants. Gel sections were dehydrated for 1 hour 
with ACN and dried in a SpeedVac (2000 rpm, 10 minutes, 4ºC). The proteins present in each 
section were reduced with 10 mM dithiothreitol (DTT) for 30 minutes at 60ºC, alkylated using 55 
mM iodoacetamide (IAA) for 30 minutes at room temperature and enzymatically digested with 
trypsin (Pierce Trypsin Protease, MS Grade, Thermo Scientific™), diluted in 50 mM ammonium 
bicarbonate, for 16 hours at 37ºC. The digestion was stopped with 10% formic acid and peptides 
were extracted from the gel fraction using 10% formic acid:ACN (1:1) for 30 minutes. Then, 
peptides were washed in ACN for 30 minutes and dried using vacuum. Finally, the peptides were 
desalted and cleaned up using OMIX Tip C18 (Agilent) (following the manufacturer’s 
instructions), dried and stored at -80ºC before LC-MS/MS analysis.  
 
3.4 Protein identification by GeLC-MS/MS 
The peptide mixes were analysed using an Orbitrap Fusion Lumos mass spectrometer 
(Thermo Scientific, San Jose, CA, USA) coupled to an EasyLC (Thermo Scientific (Proxeon), 
Odense, Denmark). Peptides were loaded directly onto the analytical column and were separated by 
reversed-phase chromatography using a 50-cm column with an inner diameter of 75 μm, packed 
with 2 μm C18 particles spectrometer (Thermo Scientific, San Jose, CA, USA). Chromatographic 
gradients started at 95% buffer A and 5% buffer B with a flow rate of 300 nl/min, gradually 
increased to 22% buffer B in 79 min and then to 35% buffer B in 11 min. After each analysis, the 
column was washed for 10 minutes with 5% buffer A and 95% buffer B. Buffer A: 0.1% formic 
acid in water. Buffer B: 0.1% formic acid in acetonitrile. 
The mass spectrometer was operated in DDA mode and full MS scans with 1 micro scans 
at resolution of 120.000 were used over a mass range of m/z 350-1500 with detection in the 
Orbitrap. Auto gain control (AGC) was set to 2E5 and dynamic exclusion to 60 seconds. In each 
cycle of DDA analysis, following each survey scan Top Speed ions with charged 2 to 7 above a 
threshold ion count of 1e4 were selected for fragmentation at normalized collision energy of 28%. 
Fragment ion spectra produced via high-energy collision dissociation (HCD) were acquired in the 
Ion Trap, AGC was set to 3e4, isolation window of 1.6 m/z and maximum injection time of 40 ms 
was used. All data were acquired with Xcalibur software v3.0.63. 
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MS/MS data from rat and rabbit samples were searched against SwissProt rat database 
(April, 2017) and rabbit database (June, 2017), respectively using the search algorithm Mascot 
version 2.5.1 (Matrix Science, http://www.matrixscience.com/). Only peptides showing a false 
discovery rate (FDR) lower than 5% were retained. Peptide intensities were normalized as a 
function of the median and positive identification required a minimum of two peptide matches. The 
LC-MS/MS analysis was performed by the CRG/UPF Proteomics Unit of the Center for Genomic 
Regulation (CGR), University Pompeu Fabra (UPF). 
3.5 Bioinformatic and Statistical analysis 
  ClueGO, a Cytoscape plug-in, was used to create molecular networks, which allowed the 
visualization of the biological processes associated to the identified proteins, and therefore help 
with attributing a biological meaning to the aggregated proteins. The proteins of different groups 
were uploaded in ClueGO as two separate clusters. This procedure was done for both animal 
models. Bioinformatic tool, DisGeNET was used to visualize networks showing the associations of 
proteins to human diseases. This analysis, that integrates data from expert curated repositories, was 
performed for proteins exclusively identified in Aged and Doxo groups. To calculate the grand 
average of hydropathy (GRAVY) value for protein sequences, online program GRAVY calculator 
(http://www.gravy-calculator.de/) was used. Online program Jvenn 
(http://bioinfo.genotoul.fr/jvenn/) was also used to create Venn diagrams. Optical density was 
calculated using Image Lab program (Supplement A and B). 
 For differential protein analysis, we first selected only proteins identified in all animals 
(n=5 in both Young and Aged group; n=5 in both Control and Doxo group). Then, a volcano plot 
was done, with each point representing a protein, and the x-axis being the log2 (fold-change) and y-
axis being -log10 (p-value) from a t-test. Each sample protein profile was normalized by dividing 
each protein area by the median of that profile. Then, the fold-change of proteins was computed by 
taken the ratio of the Aged samples and Young samples. The same procedure was applied to 
proteins from Control and Doxo groups. To improve statistical analysis insight, the Cohen’s d or 
magnitude assessment, calculated as the difference between the means of two groups divided by 
pooled standard deviation of the groups as well as its 95% confidence interval (CI) were performed 
(Supplement C and D). Proteins whose CI do not include zero were selected. Proteins were 
considered markedly increased or decreased if they have -log10 p-value>1.301 (log10 of 0.05), log2 
(fold-change) <-1 or >+1 and 95% magnitude CI different from zero. t-test was used to evaluate the 
differences between groups, making use of GraphPad Prism software (version 6.0). Results are 
presented as mean ± Standard Error of Mean (SEM). p<0.05 was considered significant. 
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4. RESULTS 
 
4.1 Methodological optimization for the isolation and characterization of the protein 
aggregates-enriched fractions 
 As mentioned before, the first goal of this thesis consisted in optimizing the technique for 
protein aggregates enrichment, based on the methodological approach described in the study of 
Ayyadevara et al. (18). We present below the most relevant experiments carried out, which allowed 
the validation of the final protocol: 
 
a) Protein precipitation method (TCA/acetone) 
In the first test, heart tissue samples were homogenized mechanically in RIPA lysis buffer 
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2.5% sodium deoxycholic, 1% NP40, 1 mM EDTA and 
protease inhibitor cocktail) using the potter homogenizer. Afterward, the lysates were incubated 
with DNase for 15 minutes at 37ºC and protein concentration was determined using DC Protein 
Assay Kit. Protein precipitation was performed in one-half of the sample, using TCA/acetone 
method. Briefly, TCA and ice-cold acetone was added to the sample in a ratio of 1:8:1, and proteins 
were precipitated for 1 hour at -20ºC. After centrifugation (18,000 x g, 15 minutes, 4ºC), pellet was 
washed with ice-cold acetone. Then the pellet was dried, suspended in HEPES buffer (0.1 M 
HEPES, pH 7.4, 1% sarcosyl, 5 mM EDTA and protease inhibitor cocktail) and centrifuged to 
obtain detergent-insoluble fraction. Finally, the pellet was dissolved in 10% SDS and the proteins 
were separated by SDS-PAGE. The results obtained are shown in Figure 6. 
 
Figure 6: Optimization of the precipitation method with TCA/acetone. SDS-PAGE of the protein aggregates-
enriched fractions obtained from healthy myocardial sample. Proteins present in half of the tissue (15 mg) were not 
subjected to TCA/acetone treatment (A), while those present in the other half (15 mg) were treated with TCA/acetone 
(B). 
 
kDa 
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Based on SDS-PAGE profiles, proteins not subjected to TCA/acetone treatment (Figure 
6A) had, apparently, greater band intensities, indicating higher protein amount, comparing to 
proteins treated with TCA/acetone (Figure 6B). Therefore, this protein precipitation method did not 
show apparent advantage. Moreover, the poor intensity of the bands may indicate that a higher 
amount of tissue is necessary. 
 
b) Sample type and quantity  
A second test was designed to evaluate different sample types, i.e., healthy and failing 
myocardial tissue (Figure 7). In this experiment, TCA/acetone protein precipitation method was 
excluded. 
 
 
Figure 7: Optimization of the protein extraction protocol for different types of samples (healthy and failing 
myocardium). SDS-PAGE of the protein aggregates-enriched fractions obtained from a failing (120 mg) (A) and a 
healthy rat heart (280 mg) (B). 
 
 
Figure 7, shows protein aggregates-enriched fractions in both failing and healthy 
myocardium. 
 
c) Sample quantity and protein precipitation method (acetone)  
 To improve the profile and purity of the sample, another method for protein precipitation 
using ice-cold acetone overnight at -20ºC, followed by centrifugation at 14,000 x g for 15 minutes 
at 4ºC was tested. Additionally, in the aging animal model, one of the major limitations was the 
amount of sample available. Hence, the next experiment had two aims: evaluate a softer protein 
precipitation method using ice-cold acetone and smaller amounts of tissue sample (20, 100, 200 
and 400 mg) (Figure 8). 
 
kDa 
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Figure 8: Optimization of the smallest quantity of tissue. SDS-PAGE of the protein aggregates-enriched fractions 
obtained from cardiac tissue of failing (8.1) and healthy rat heart (8.2). Corresponding protein mass (A) to the 
different amounts of tissues tested (B). 
 
As presented in Figure 8, all quantities of tissue tested seemed to yield sufficient amount of 
protein aggregates-enriched fractions, as seen by intensity of the bands. Nevertheless, when starting 
with at least 100 mg of tissue, a consistent dragging across the lane (Figure 8) was observed, 
evidencing protein overload. In both tests, with the smallest amount of tissue tested (20 mg) and the 
ice-cold acetone precipitation method, a “clean” profile of aggregated proteins was obtained. 
In order to evaluate the possibility of working with even smaller amounts of sample, 5, 10, 
20 and 30 mg of tissue were tested. Results obtained are shown in Figure 9.  
 
 
 
Figure 9: Optimization of the smallest quantity of tissue. SDS-PAGE of the protein aggregates-enriched fractions 
obtained from cardiac tissue of failing (9.1) and healthy rat heart (9.2). Corresponding protein mass (A) to the 
different amounts of tissues tested (B). 
 
Both experiments showed enriched fractions in aggregated proteins independently of the 
amount of protein tested. 
8.2 8.1 
9.2 9.1 
kDa kDa 
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d) Potter vs beads based mechanical homogenization  
In attempt to maximize protein extraction from the myocardial sample, a new type of tissue 
homogenization was used instead of the potter-based mechanical homogenization system. This 
time, a bead system was used instead of the potter homogenizer (Figure 10).  
 
 
  
Figure 10: Optimization of the homogenizing method. SDS-PAGE of the protein aggregates-enriched fractions 
obtained from cardiac tissue of failing (10.1) and healthy rat heart (10.2). Corresponding protein mass (A) to the 
different amounts of tissues tested (B). 
 
With beads homogenizing method, it was possible to obtain a “cleaner” profile of 
aggregated proteins using only 5 and 10 mg of tissue (Figure 10). Besides, using the same type and 
the same amount of tissue, the beads system increased the protein extraction yield in comparison to 
the potter homogenizer (Table 1). Failing myocardium showed more than a 2-fold increase in 
protein extraction yield, while in the healthy myocardium the increase was over 1.5-fold (Table 1).  
 
Table 1: Protein extraction yield obtained from different amounts and types of sample using distinct tissue 
homogenization methods. Corresponding protein yield (%) (total protein mass (mg) / tissue mass (mg) x 100) to the 
different amounts of tissues tested (mg) obtained using two types of tissue homogenization (potter (P) or beads (B) 
system). Tests were performed using cardiac tissue from failing and healthy rat hearts. 
 
 
 
 Tissue mass (mg) Protein mass (mg) Protein Yield (%) 
Failing myocardial 
sample 
10 0.7 (P) 7 
1.6 (B) 16 
20 1.4 (P) 7 
3.3 (B) 16.5 
 
Healthy myocardial 
sample 
5 0.7 (P) 14 
1.2 (B) 24 
10 1.3 (P) 13 
2.4 (B) 24 
10.1 10.2 
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Table 2: Protein extraction yield obtained from different amounts of samples. Corresponding protein yield (%) 
(protein aggregates-enriched fraction mass (mg) / total protein mass (mg) x 100) to the different amounts of tissues 
tested (mg), obtained with or without acetone treatment for protein precipitation. Tests were performed using 
cardiac tissue from failing and healthy rat hearts. 
e) Optimization of aggregate proteins amount for GeLC-MS/MS analysis 
After optimizing the conditions for protein aggregates enrichment, the amount of existing 
protein in these aggregates was evaluated. Therefore, in the next experiment, the method’s 
reproducibility was tested and the amount of aggregated proteins was assessed to determine its 
suitability for GeLC-MS/MS analysis. Hence, two different tissue amounts (5 and 10 mg) were 
tested (Figure 11). The impact of acetone-based precipitation method on the aggregated proteins 
mass was also evaluated (Table 2).  
 
  
Figure 11: Evaluation of protein precipitation method and optimization of smallest amount of tissue for an 
adequate protein aggregates enrichment. SDS-PAGE of the protein aggregates-enriched fractions obtained from 
cardiac tissue of failing (11.1) and healthy rat heart (11.2), previously treated or non-treated with acetone. 
Corresponding protein mass (A) to the different amounts of tissues tested (B). 
 
 
 
 
 
As shown in Figure 11, the method was reproducible as the band profile obtained was 
similar to previous gels, as seen, for example, by the presence of the bands with estimated 
molecular weights of 245, 100 and 75 kDa. Moreover, 5 mg of tissue is sufficient to proceed to 
GeLC-MS/MS. Besides, treatment with acetone increased the protein extraction yield in both 
 With acetone Without acetone 
Failing myocardial 
sample 
Tissue mass (mg) 5 10  5 
Protein aggregates-enriched 
fraction mass (mg) 
0.493 1.246  0.420 
Protein yield (%) 70 88  59 
Healthy myocardial 
sample 
Tissue mass (mg) 5 10  10 
Protein aggregates-enriched 
fraction mass (mg) 
0.482 1.288  0.870 
Protein yield (%) 37 49  33 
11.1 11.2 
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Table 3: Corresponding protein aggregates-enriched fraction mass (mg) to the 5 mg of tissue tested. Tests were 
performed using heart tissue from rabbits treated with vehicle and with Doxo. 
 
failing and healthy myocardial samples when compared to those untreated, thereby showing the 
advantage of using a softer precipitation method (Table 2). 
 
f) Protocol reproducibility in myocardial samples from New Zealand rabbits 
The aim of this thesis was to study protein aggregates-enriched fractions from two different 
animal models, which imply distinct species. All protocols, mentioned before, were tested in 
myocardial samples from rats (Rattus norvegicus), confirming its suitability. Thus, we needed to 
validate the optimized protocol in myocardial samples from New Zealand rabbits (Oryctolagus 
cuniculus) (Figure 12). 
 
  
Figure 12: Suitability of the optimized protocol for myocardial samples from New Zealand white rabbits. 
SDS-PAGE of the protein aggregates-enriched fractions obtained from New Zealand white rabbits cardiac tissue 
treated with vehicle (12.1) and treated with Doxo (12.2). Corresponding protein mass (A) to the different amounts of 
tissues tested (B). 
 
 
 
   
 Tissue mass (mg) Protein aggregates-enriched fraction mass (mg) 
Control 5 0.285 
Doxo 5 0.340 
 
The SDS-PAGE profiles from Figure 12 demonstrated that this protocol was also 
applicable in New Zealand white rabbit’s myocardial samples. Furthermore, these results showed 
that 5 mg of tissue seems to be enough to obtain a “clean” profile of aggregated proteins. 
All the conditions tested are summarized in Figure 13. 
12.2 12.1 
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Figure 13: Overview of all experimental conditions tested over to baseline protocol. The optimized conditions are 
marked in red and are suitable for both animal models. 
 
  
4.2 Optimized protocol for the isolation of protein aggregates-enriched fractions 
 After optimizing the methodology for protein aggregates enrichment it was possible to 
achieve a final protocol, described below. LV were defrosted, weighted and suspended in RIPA 
lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2.5% sodium deoxycholic, 1% NP40, 1 mM 
EDTA and protease inhibitor cocktail). Tissue homogenization was performed at a speed of 6500 
rpm for 6 cycles of 30 seconds, using MagNA Lyser Instrument (Roche Diagnostics). 
Homogenates were centrifuged (16 060 x g, 5 minutes, 4ºC) to remove debris, organelles and 
particulates. The supernatants were incubated with DNase type I (NZYTech) for 15 minutes at 
37ºC, followed by centrifugation (2 000 x g, 5 minutes). The protein concentration was determined 
using DC™ Protein Assay Kit (Bio-Rad). Protein samples were precipitated with ice-cold acetone 
overnight at -20ºC, followed by centrifugation at 14 000 x g for 15 minutes at 4ºC. Pellets were 
suspended in HEPES buffer (0.1 M HEPES, pH 7.4, 1% sarcosyl (w/v), 5 mM EDTA and protease 
inhibitor cocktail), and, subsequently, samples were centrifuged for 35 minutes at 100,000 x g, 4ºC. 
Detergent-insoluble fractions were collected and suspended in 30 µL SDS 10%, and an aliquot was 
taken to perform protein quantification. Proteins were suspended in SDS-PAGE loading buffer (0.5 
M Tris-HCL pH 6.8, 50% glycerol, 10% SDS, bromophenol blue, 20% mercaptoethanol) and 
dissolved by heating for 10 minutes at 100ºC. Protein components of aggregate fractions were 
separated by 12% SDS-PAGE gel for 45 minutes at 200V. The resulted gel was stained with 
Coomassie Brilliant Blue G-250 (Bio-Rad) and visualized on ChemiDoc™ XRS Gel Imaging 
System (Bio-Rad). 
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4.3 Aging animal model 
4.3.1 Characterization of the protein aggregates-enriched fractions isolated from left 
ventricle of young and aged rats  
 
Protein aggregates-enriched fractions from LV of Young and Aged WKY rats were 
isolated and separated by SDS-PAGE (Figure 14).  
   
 
  
Figure 14: SDS-PAGE of the protein aggregates-enriched fractions obtained from LV of Young (Y) and Aged (A) 
WKY rats.  
 
 The band profiles obtained seem to be similar between Young and Aged rats. Furthermore, 
percentage of protein aggregates-enriched fractions was also determined and no significant 
differences were found between groups (Young=7.20±0.80 vs Aged=9.20±0.80, p=0.1151) (Figure 
15). 
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Figure 15: Percentage of the LV protein aggregates-enriched fractions determined for Young and Aged WKY rats. 
Values are represented by mean ± SEM. n=5 in each group. 
 
 
4.3.2 Proteomic analysis after GeLC-MS/MS 
Total protein aggregates-enriched fractions 
In order to characterize protein aggregates-enriched fractions from Young and Aged rats 
myocardium, proteins from aggregates-enriched fractions were separated by SDS-PAGE, digested 
in-gel with trypsin and the peptides separated and analyzed by GeLC-MS/MS. This analysis 
allowed the identification of 2470 proteins with FDR<5%. After removing contaminants and select 
proteins with two or more peptides identified, a total of 1357 proteins were obtained.  
The protein aggregates-enriched fractions were evaluated resulting in the identification of 
1279 proteins in Young group and 1260 in Aged group. To characterize the exclusive aggregated 
proteins of each group, a Venn diagram was created using jvenn (Figure 16). 
 
   
 
 
Figure 16: Venn diagram showing the distribution of protein aggregates-enriched fractions identified in Young and 
Aged groups (1279 and 1260, respectively): 1182 proteins are common in both groups; 97 proteins are exclusive of 
Young group and 78 proteins of Aged group. 
 
Young Aged 
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 As shown in Figure 16, 97 and 78 proteins were exclusively found in Young and Aged rats 
myocardium, respectively, which mean that about 87% of aggregated proteins are shared by both 
groups.  
 
Hydropathy analysis 
A property that strongly influences the aggregation propensity of a protein sequence is its 
hydrophobicity. In neurodegenerative diseases, proteins propensity for aggregation are more 
hydrophobic (102). Take that into account, we evaluate if the proteins that aggregate in heart tissue 
follow the same profile. We used the grand average of hydropathy (GRAVY) value as measure of 
the hydrophobicity of proteins. The GRAVY value, defined by the sum of hydropathy values of all 
amino acids divided by the protein length, was calculated for all aggregated proteins identified in 
Young and Aged groups (Figure 17).   
 
Figure 17: Protein GRAVY analysis. GRAVY value calculated for protein sequences identified in Young and Aged 
WKY rats. Values are represented by mean ± SEM.  
 
This analysis revealed that hydropathy value does not change between groups (Young=-
0.3286±0.0087; Aged=-0.3341±0.0088, p=0.6584), and that the majority of this aggregated 
proteins are hydrophilic, regarding that hydropathy value was negative. 
 
 
Biological processes  
With the purpose of ascertain the biological processes associated with proteins identified in 
both groups, ClueGO bioinformatic tool was used. For cluster analysis in ClueGO, we defined two 
protein groups - cluster 1 (marked by red color): aggregated proteins identified in Aged 
myocardium; cluster 2 (marked by green color): aggregated proteins identified in Young 
myocardium). Thus, a molecular network was created, to visualize which biological processes 
belong to each cluster (Figure 18). 
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Figure 18: ClueGO network representing the main biological processes associated with aggregated proteins identified in Young and Aged rats myocardium. Each node represents 
a biological process and edges represent the connections between the nodes. Green part of each node represents the percentage of proteins identified in Young group that are related with 
that node biological process. Red part of each node represents the percentage of proteins identified in Aged group that are related with that biological process. 
35 
 
As observed in Figure 18, most of the biological processes are associated with both Young 
and Aged groups, since the green and red parts of the nodes are equal. However, biological 
processes such as homeostatic process, mitochondria organization, generation of precursor 
metabolites and energy, cell death, phosphorylation, intracellular transport, among others, are more 
representative of the Young group, which are represented by nodes with higher proportion of green. 
Likewise, regulation of cardiac muscle contraction, cardiac contraction, muscle structure 
development, organelle organization and its regulation, among others, are the most relevant in 
Aged group, being the proteins associated with these biological processes more predominant in this 
group. 
 
 
Differential protein analysis 
To evaluate the proteins that significantly differ in abundance in each group, a differential 
protein analysis was done taking into consideration the proteins identified in all rats (Figure 19). 
 
 
Figure 19: Volcano plot of all proteins identified with two or more peptides in 10 animals (5 Young vs 5 Aged 
rats). Each point represents a protein plotted as a function of log2 (fold-change: Aged/Young) and -log10 (p-value). Blue 
points correspond to the non-significantly deregulated proteins; orange points correspond to the non-consistently 
deregulated proteins; green points correspond to proteins consistently deregulated (represented by their UniProt KB 
code). 
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Table 4: Full list of proteins (and their UniProt KB code) identified in aggregates-enriched fractions that were 
differentially increased in Young (log2 (Aged/Young) <-1) and Aged (log2 (Aged/Young) >+1) myocardium.  
 
 
Differences in protein amounts between Young and Aged myocardium are represented 
according to their p-value and fold-change (Figure 19). Blue points represent the non-significantly 
deregulated proteins, whereas orange and green points represent statistically significantly 
deregulated proteins. But only proteins represented by green points passed the magnitude test, 
which means that these proteins are consistently deregulated in the group. Among these, only 
proteins with log2 (Aged/Young) <-1 or >+1 were considered differentially increased between the 
two groups. In this way, proteins with log2 (Aged/Young) less than -1 are markedly increased in 
Young group, and consequently, decreased in Aged group. Likewise, proteins with log2 
(Aged/Young) greater than +1 are markedly increased in Aged group and conversely decreased in 
Young group. In this case, 15 and 18 proteins were significantly increased in Young and Aged 
groups, respectively, as described in Table 4.  
 
 
 
Proteins increased in Young group Proteins increased in Aged group 
P40329: Arginine--tRNA ligase, cytoplasmic Q64591: 2,4-dienoyl-CoA reductase, 
mitochondrial 
P51868: Calsequestrin-2 P35738: 2-oxoisovalerate dehydrogenase subunit 
beta, mitochondrial 
Q7TP52: Carboxymethylenebutenolidase 
homolog 
Q64057: Alpha-aminoadipic semialdehyde 
dehydrogenase 
P61016: Cardiac phospholamban P21396: Amine oxidase [flavin-containing] A 
P41350: Caveolin-1 P47853: Biglycan 
P51638: Caveolin-3 P24268: Cathepsin D  
P10888: Cytochrome c oxidase subunit 4 isoform 
1, mitochondrial 
P85125: Caveolae-associated protein 1 
P12075: Cytochrome c oxidase subunit 5B, 
mitochondrial 
P04797: Glyceraldehyde-3-phosphate 
dehydrogenase 
P11951: Cytochrome c oxidase subunit 6C-2 P51886: Lumican 
P35171: Cytochrome c oxidase subunit 7A2, 
mitochondrial 
Q62667: Major vault protein 
Q62698: Cytoplasmic dynein 1 light intermediate 
chain 2 
P16409: Myosin light chain 3 
Q5XI81: Fragile X mental retardation syndrome-
related protein 1 
P02563: Myosin-6 
Q80W89: NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 11 
P02564: Myosin-7 
P29457: Serpin H1 O88483: [Pyruvate dehydrogenase [acetyl-
transferring]]-phosphatase 1, mitochondrial 
P06686: Sodium/potassium-transporting ATPase 
subunit alpha-2 
P49432: Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial 
 
 
 
 
O35413: Sorbin and SH3 domain-containing 
protein 2 
P28480: T-complex protein 1 subunit alpha 
P22985: Xanthine dehydrogenase/oxidase 
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Human diseases associated with aggregated proteins  
Analysis of proteins aggregates-enriched fractions from Young and Aged LV revealed that 
78 proteins were exclusively aggregated in Aged hearts. In this way, to get more information about 
the biological relevance of these aggregated proteins, we investigated their association with human 
diseases. For this purpose, a Curated DisGeNET network was created (Figure 20). 
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Figure 20: DisGeNET network representing the diseases associated with proteins exclusively aggregated in Aged group. Smaller nodes and those more blue correspond to proteins 
or diseases with few interactors. Larger nodes and those more orange correspond to proteins or diseases with more interactors. 
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 This network provides information about which proteins are related to which human 
diseases. Several cardiovascular diseases, such as cardiomyopathy, myocardial infarction, coronary 
heart disease are associated with proteins that aggregate exclusively during aging, including 
tropomyosin alpha-1 chain, transcription activator BRG1 and vascular endothelial growth factor 
receptor 1. These findings suggest a possible involvement of these proteins in the pathophysiology 
of cardiac aging.  
 
 
4.4 Doxo-induced cardiotoxicity animal model 
4.4.1 Characterization of the protein aggregates-enriched fractions isolated from left 
ventricle of Control and Doxo-treated rabbits  
Protein aggregates-enriched fractions from the LV of New Zealand rabbits were also 
isolated and separated by SDS-PAGE (Figure 21), according the optimized protocol. 
  
  
Figure 21: SDS-PAGE of the protein aggregates-enriched fractions obtained from LV of Control (C) and Doxo-
treated (D) rabbits.  
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SDS-PAGE profiles, observed in Figure 21, were similar in Control and Doxo-treated 
animals. Similarly to the aging model, no significant differences were found in the percentage of 
protein aggregates-enriched fractions between groups (Control=9.400±1.691; Doxo=9.600±2.272, 
p=0.9454) (Figure 22).  
 
 
4.4.2 Proteomic analysis after GeLC-MS/MS 
Total protein aggregates-enriched fractions  
Identification of proteins present in aggregates-enriched fractions from Control and Doxo-
treated rabbits was performed by GeLC-MS/MS, allowing the identification of 661 proteins with 
FDR<5%. After removing contaminants and select proteins with two or more peptides identified, a 
total of 287 proteins were obtained.  
The total protein aggregates-enriched fractions were evaluated resulting in the 
identification of 274 proteins in Control group and 267 in Doxo group. Then, a Venn diagram was 
created to characterize the aggregated proteins exclusive of each group (Figure 23).   
 
Figure 23: Venn diagram showing the distribution of protein aggregates-enriched fractions identified in Control and 
Doxo groups (274 and 267, respectively): 254 proteins are common in both groups; 20 proteins are exclusive of 
Control group and 13 proteins of Doxo group.  
 
 
Figure 22: Percentage of the LV protein aggregates-enriched fraction determined for Control and Doxo-treated 
rabbits. Values are represented by mean ± SEM. n=5 in each group. 
Control Doxo 
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As shown in Figure 23, 20 and 13 proteins were exclusively found in Control and Doxo-
treated rabbits, respectively, which mean that about 89% of aggregated proteins are shared by both 
groups.  
 
Hydropathy analysis 
To infer about the hydrophobicity or hydrophilicity of the proteins, GRAVY was 
calculated for all aggregated proteins identified in Control and Doxo-treated rabbits (Figure 24).   
 
 
Figure 24: Protein GRAVY analysis. GRAVY value calculated for protein sequences identified in Control and Doxo-
treated rabbits. Values are represented by mean ± SEM.  
 
This analysis revealed that hydropathy value is similar between groups (Control=-
0.3143±0.0230; Doxo=-0.3177±0.0235, p=0.9192), and that the majority of this aggregated 
proteins are hydrophilic. 
 
Biological processes  
For cluster analysis in ClueGO, we used the two protein groups - cluster 1 (marked by red 
color): aggregated proteins identified in Doxo myocardium; cluster 2 (marked by green color): 
aggregated proteins identified in Control myocardium. Regarding molecular network, only few GO 
annotations/terms were visualized because the database for the Oryctolagus cuniculus species was 
from 2014 terms (data not shown). Consequently, BLAST analysis was performed for sequence 
alignment with proteins from Homo sapiens, being selected proteins with ≥95% of homology. 
Then, a molecular network was constructed accordingly to the biological processes associated with 
identified proteins (Figure 25). 
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Figure 25: ClueGO network representing the main biological processes associated with aggregated proteins 
identified in Control and Doxo-treated rabbits’ myocardium. Each node represents a biological process and edges 
represent the connections between the nodes. Green part of each node represents the percentage of proteins identified in 
Control group that are related with that biological process. Red part of each node represents the percentage of proteins 
identified in Doxo group that are related with that biological process. 
 
 
As observed in Figure 25, most of the biological processes are associated with both Control 
and Doxo groups, since the green and red parts of the nodes are equal. However, biological 
processes such as ADP metabolic process are representative of the Control group, since these nodes 
have higher proportion of green. Likewise, regulation of cardiac contraction, cardiac conduction, 
platelet aggregation, among others, are representative of the Doxo group, since these biological 
processes have higher percentage of proteins identified in Doxo group. 
 
 
Differential protein analysis 
To evaluate the proteins that are markedly increased or decreased in both groups, a 
differential protein analysis was done considering the proteins identified in all rabbits (Figure 26).  
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Figure 26:  Volcano plot of all proteins identified with two or more peptides in 10 animals (5 Control vs 5 Doxo-
treated rabbits). Each point represents a protein plotted as a function of log2 (fold change: Doxo/Control) and -log10 (p-
value). Blue points correspond to the non-significantly deregulated proteins; orange points correspond to the non-
consistently deregulated proteins; green points correspond to proteins consistently deregulated (represented by their 
UniProt KB code). 
 
Proteins represented by green points with log2 (Doxo/Control) <-1 or >+1 were considered 
differentially deregulated between the two groups. In this way, proteins with log2 (Doxo/Control) 
less than -1 are markedly increased in Control group, and consequently, decreased in Doxo group. 
Likewise, proteins with log2 (Doxo/Control) greater than +1 are markedly increased in Doxo group, 
and conversely, decreased in Control group. In this case, only histidine-rich glycoprotein showed to 
be increased in Doxo group. 
 
 
Human diseases associated with aggregated proteins  
Analysis of aggregates-enriched fractions from Control and Doxo hearts revealed that 13 
proteins were exclusively aggregated in Doxo-treated animals. In this way, a Curated DisGeNET 
network was created, in order to evaluate the association between exclusively aggregated proteins 
in Doxo group with human diseases (Figure 27). 
 
44 
 
 
Figure 27: DisGeNET network representing the diseases associated with proteins exclusively aggregated in Doxo 
group. Smaller nodes and those more blue correspond to proteins or diseases with few interactors. Larger nodes and those 
more orange correspond to proteins or diseases with more interactors. 
 
 
As expected, several cardiovascular diseases, such as cardiomyopathies, myocardial 
ischemia and HF, are associated with proteins that aggregate exclusively after Doxo treatment, 
suggesting a possible involvement of these proteins in Doxo-induced cardiotoxicity. 
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5. DISCUSSION  
5.1 Methodological optimization for the isolation and characterization of the protein 
aggregates-enriched fractions 
The first aim of this thesis was to optimize the methodology for the isolation and 
characterization of compact protein aggregates from cardiac tissue from rats and rabbits, based on 
the method described by Ayyadevara et al. (18). Our concern was to report all conditions tested 
during the experimental implementation. Therefore, two steps were added over Ayyadevara et al. 
(18) protocol: degradation of genomic DNA with a DNase treatment and protein purification by 
precipitation with TCA/acetone. In fact, after protein extraction, removal of all types of 
contaminants such as detergents, lipids and nucleic acids is essential, since they may interfere with 
downstream applications (100). The visualization of the resulting gel revealed no differences 
between the SDS-PAGE profiles of the sample treated with TCA/acetone comparing to the non-
treated sample. This protein precipitation method is often used, however it presented an apparent 
disadvantage due to the probable protein loss during the procedure, caused by incomplete 
solubilization of the pellets and the acetone washing step (103). Since TCA is a strong acid, the 
resulting pellet was usually hard to dissolve (104), being extremely time-consuming, so in the 
subsequent tests this method was removed. Additionally, the poor intensity of the bands observed 
in the gel was possibly due to the fact not all sample was properly loaded into the gel (since the 
pellet was hard to dissolve) or may indicate that a higher amount of sample (>15 mg) is required to 
achieve a better protein aggregates-enriched fractions profile. 
In the second test, two distinct amounts of LV from different animal models were tested. 
Based on gel analysis it was possible to obtain protein aggregates-enriched fractions, thereby 
demonstrating that the methodology worked both in healthy and failing myocardial samples. 
Interestingly, the SDS-PAGE profile showed that lane A displays higher amounts of aggregates 
comparing to lane B, despite starting with smaller amount of tissue. These differences may be due 
to sample type, it is expected that failing hearts present more protein aggregates since protein 
quality control can be already compromised. The third test aimed to improve the purity and, 
consequently, to avoid sample dragging later on the SDS-PAGE profiles. To achieve this, we used 
protein precipitation method with ice-cold acetone. This method has the advantage of being simple 
to perform and removing interfering species, such as lipids, genomic DNA and detergents, which 
proved to maximize the recovery of proteins in small samples. These findings are in agreement 
with a previous study performed in brain tissue samples, in which protein precipitation using 
acetone resulted in a greater protein recovery and in less time to solubilize the protein pellet, 
comparing to TCA/acetone method (103). Since the amount of LV available is very limited in the 
aging animal model, it was essential to introduce this step in the protocol, in order to obtain 
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maximal protein aggregates-enriched fractions recovery from minimal tissue amounts, such as 10 
mg of tissue.  
Obtaining high quality and high yield of proteins is an important factor for further 
downstream protein characterization methods, such as in SDS-PAGE and MS (100). In fact, protein 
yield depends on the type of homogenization method selected (105, 106). Thus, in a fifth 
experiment, other homogenizing method using a beads system was tested and compared to the 
previously potter-based mechanical homogenization. Beads homogenizer proved to be a more 
promising methodology, because the protein yield obtained from the same amount of tissue was 
always higher compared to potter homogenizer. With this protein extraction method, 5 mg of tissue 
was enough to obtain a “clean” profile of the protein aggregates-enriched fractions, thereby solving 
the problem of limited amount of tissue. Therefore, beads homogenizer is an efficient method, 
which ensures efficient disruption, homogenization, as well as higher yields of proteins comparing 
with potter homogenizer. 
According to Aye et al. (107) work, more than 2200 LV proteins could be identified, with a 
FDR <1% through trypsin-based in-gel digestion followed by GeLC-MS/MS analysis. In such 
study, 50 µg of proteins were loaded into the gels, thus this value served as reference for this study. 
Taking this into account, the purpose of the sixth test was to determine if the amount of proteins 
loaded into the gel was satisfactory to perform a GeLC-MS/MS analysis. Furthermore, the impact 
of protein precipitation with acetone on the aggregated proteins yield was evaluated. Firstly, results 
demonstrated reproducibility of the optimized method, because the SDS-PAGE profiles were 
similar to previous tests using the same amount and type of sample. In fact, the use of acetone as 
precipitation method improved protein extraction yield of protein aggregates-enriched fractions, 
relative to the same amount of tissue, in both failing and healthy myocardial samples. Furthermore, 
treatment with acetone seems to be important to preserve low molecular weight proteins. We were 
also able to show that 5 mg of tissue is enough to obtain 10 times more protein aggregates-enriched 
fraction than the amount necessary to perform a GeLC-MS/MS with trypsin in-gel digestion (107). 
This amount of tissue displayed a good definition of the bands and not a trawling, as observed for 
the double amount of tissue (10 mg). Moreover, the resulting pellet was smaller and the 
solubilization was easier, avoiding sample loss in this step. 
After optimizing the conditions for aggregates enrichment, the last experiment aimed to 
test if this method was also applicable in a different animal species other than rat, Oryctolagus 
cuniculus, i.e. New Zealand white rabbits. Both animals that received vehicle or Doxo were 
analysed showing a “clean” SDS-PAGE profile, suitable for studying myocardial protein 
aggregates in this species. Again 5 mg of tissue provided a good band definition and was enough to 
obtain more than 50 µg of proteins, reaching the goal defined in the study of Aye et al. (107) 
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5.2 Proteomic analysis of protein aggregates-enriched fractions  
Defects on protein quality control promote loss of protein homeostasis, which leads to 
accumulation of misfolded proteins and protein aggregates, with consequent toxic effects to the 
cells. Impaired proteostasis is particularly detrimental to cardiomyocytes since they have restrictive 
regenerative capacity (54). Therefore, maintaining balanced protein quality control is fundamental 
to minimize cellular dysfunction and death (2). For this reason, the identification of aggregated 
proteins provides a starting point to understand their influence in collapse of protein homeostasis in 
both aging and cardiotoxicity conditions. Regarding methodological approach used in the present 
work, it is important to mention that protein aggregates are insoluble in sarcosyl (18), thus, 
information derived from soluble aggregates might have been disregarded. 
 
Cardiovascular impact of aging in protein aggregation 
As mentioned before, during physiological aging protein homeostasis gradually becomes 
compromised and several proteins tend to aggregate (108). Previous study demonstrated that hearts 
from aged mice showed an increase in the number and abundance of aggregated protein 
components, relative to those from young-adult mice (18). Surprisingly, patterns and intensities of 
the bands as well as the percentage of protein aggregates-enriched fractions found in our work were 
similar between Young and Aged hearts (supplement A). So, despite no differences were observed 
in the relative amount of protein aggregates-enriched fractions between both groups, the type of 
proteins present in those fractions are associated to distinct physiologic roles in this specific animal 
model. Thus, as expected, we found differences in protein constituents of age-derived aggregates. 
In fact, GeLC-MS/MS analysis of protein aggregates provides identification of distinct proteins in 
Young and Aged groups, being 97 and 78 proteins exclusively identified in Young and Aged 
hearts, respectively, suggesting that aging promotes aggregation of different proteins when 
compared to their young counterparts. Nowadays, it is well known that neurodegenerative diseases, 
such as Alzheimer’s disease, are intimately related to protein aggregation, which is involved in 
their pathophysiology. The protein aggregate, in this neurodegenerative disease, is predominantly 
constituted by a higher amount of hydrophobic proteins, which are more susceptible to aggregation 
(102). However, in our study we did not find the same profile of proteins in the LV tissue. In fact, 
GRAVY analysis revealed no differences between the two groups and mostly of the proteins found 
in the aggregates from both groups were in general more hydrophilic. This finding suggests that 
protein aggregation pattern in cardiac tissue may differ from that in nervous tissue, namely in 
intensity, mechanisms underlying aggregation and proteins heterogeneity.  
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Nowadays, bioinformatic analysis provide researchers the possibility to have insights into 
the specific biological processes associated with proteins identified in different conditions, such as 
the ones observed in protein aggregates-enriched fractions. Therefore, it is useful to pinpoint 
potentially deregulated biological processes that occur during the natural course of aging. Most of 
the biological processes presented in the ClueGO network are equally shared by the two groups, 
observed by the equivalent percentage of green (Young group) and red (Aged group) parts in 
several nodes. Indeed, this outcome was expected since 87% of total protein aggregates-enriched 
fractions were common to both groups. Nevertheless, there were specific biological processes such 
as homeostatic process, mitochondria organization, generation of precursor metabolites and energy, 
cell death, representative of the Young group, suggesting that protein aggregation is a normal 
physiological event that plays an important role in the maintenance of cardiac structure and 
function even under healthy conditions. In fact, aggregated proteins associated with mitochondria 
organization, which includes mitochondrial morphogenesis and distribution, replication of the 
mitochondrial genome and synthesis of new mitochondrial components, may be due to the increase 
of mitochondria biogenesis in Young hearts when compared to Aged hearts (109-111). Thus, the 
protein aggregates present in Young group could be linked to the more efficient/higher protein 
turnover (112) that occurs at this age, therefore representing a vital regulatory/basal mechanism for 
the elimination of damaged proteins or organelles. On the other hand, we also noticed that specific 
biological processes are more representative of the Aged group, which include regulation of cardiac 
muscle contraction, cardiac contraction, organelle organization and regulation, among others. The 
presence of proteins involved in cardiac contraction in aggregates from aged hearts has already 
been reported (18). This finding may possibly suggest that the dysfunction with posterior 
accumulation of these proteins can contribute to cardiac contractility impairment observed during 
the natural process of aging. At the same time, aging has been related with modifications in 
structure and organization of several organelles, namely mitochondria (113), which support our 
results, taking into account that proteins involved in this biological process were more abundant in 
aggregates from Aged hearts. 
Differential protein analysis of aggregates revealed 33 proteins that significantly differ in 
abundance between Young and Aged hearts, from which 18 proteins were markedly increased with 
age. Cardiac contractility and relaxation are regulated by Ca
2+
 homeostasis. Several proteins 
present in SR, such as Ca
2+
-ATPase (SERCA), phospholamban, calsequestrin-2 and ryanodine 
receptors (RyR), play a key role in regulation of intracellular Ca
2+
-handling. SERCA is responsible 
for the sequestration of cytosolic Ca
2+
 into SR lumen, being regulated by phospholamban. In this 
way, dephosphorylated phospholamban can interact with SERCA, decreasing its pumping activity, 
whereas phosphorylated phospholamban increase afﬁnity of SERCA for Ca2+. On the other hand, 
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calsequestrin-2 is the major Ca
2+
-binding protein in cardiomyocytes, playing an important function 
in Ca
2+
 storage and in regulation of Ca
2+
 release from SR into cytosol via RyR (114). These two 
proteins, phospholamban and calsequestrin-2, were markedly increased in protein aggregates from 
Young group. Moreover, sodium/potassium-transporting ATPase (Na
+
/K
+
-ATPase) subunit alpha-2 
was also increased in Young hearts. Na
+
/K
+
-ATPase is a transmembrane protein that catalyzes the 
active transport of Na
+
 and K
+ 
across the plasma membrane, thereby regulating the membrane 
potential, creating a Na
+
 transmembrane gradient and, indirectly, cardiac contractility. This protein 
is composed by distinct isoforms: catalytic α-subunit isoform (α1, α2 or α3) and β-subunit isoform 
(β1 or β2). Na+/K+-ATPase isoforms play a significant role in regulating myocardial function 
during development stages, as well as in pathological conditions, like hypertension. Interestingly, 
during postnatal maturation, the α3 isoform is replaced by α2 isoform, presenting higher expression 
and activity of this isoform in adult rat heart (115). The higher abundance of phospholamban, 
calsequestrin-2 and Na
+
/K
+
-ATPase isoform α2 in aggregates from Young hearts may suggest a 
higher turnover/renovation of these proteins in order to maintain cardiomyocytes physiological 
demands of the faster, healthier and more contractile hearts of the Young group (116). 
Cardiac muscle requires considerable amounts of ATP daily, which is supplied mainly by 
mitochondrial oxidative phosphorylation, to sustain normal contractile activity. So, balancing 
mitochondrial biogenesis and removal of damaged mitochondria by mitophagy is crucial for 
keeping a healthy population of mitochondria, ATP production and cellular homeostasis. However, 
several factors, such as aging, failure to preserve the critical balance between mitochondrial 
biogenesis and mitophagy, leading to an increase of dysfunctional mitochondria that contribute to 
several diseases (60, 109-111). Aggregates from Young hearts revealed higher abundance in 
mitochondrial proteins, more specifically in cytochrome c oxidase of the mitochondrial respiratory 
chain, which is the terminal enzyme complex of the mitochondrial electron transport chain. These 
findings can be explained by the increase in mitochondrial biogenesis to support the elevated 
energy requirements of the young cardiomyocytes. Thus aggregation of these proteins is possibly 
due to the higher protein renewal at this age that slows down with aging. 
Among the most abundant proteins in the aggregates from Aged group we also found 
mitochondrial proteins, such as monoamine oxidase (MAO). As mentioned before, oxidative stress 
is one of the factors involved in pathophysiology of HF and cardiac aging (17, 58). Among the 
sources of oxidative stress, the mitochondrial enzymes MAO has been proposed to be a great 
contributor to ROS production in the heart. These enzymes, that exist in two isoforms MAO-A and 
MAO-B, are responsible for oxidative deamination of neurotransmitters and exogenous amines, 
resulting in H2O2 production (117, 118). Our results showed that MAO-A is increased in 
aggregates from aged hearts. Interestingly, MAO-A activity is increased in rat models of HF and 
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cardiac aging (117, 119), as well as MAO-A-dependent H2O2 production, suggesting that this 
enzyme is one of the major factors involved in cardiac oxidative stress during aging (117). 
Villeneuve et al. showed that increasing MAO-A expression, to pathophysiological levels observed 
in failing and aging hearts, trigger deleterious effects in the heart such as oxidative stress increase, 
mitochondrial damage and peroxisome proliferator-activated receptor-c coactivator-1 α (PGC-1α) 
downregulation (a master regulator of mitochondrial biogenesis), contributing to cardiomyocyte 
necrosis and HF (119). Moreover, MAO-A-dependent ROS production disrupts autophagic flux, 
leading to dysfunctional mitochondria accumulation and cell death (118). Interestingly, we 
observed that MAO-A aggregation was increased in aged hearts, that could be seen as a protective 
mechanism, to avoid MAO-A-dependent ROS production deleterious effects, and therefore the cell, 
probably, try to remove/eliminate this protein through aggregation. Furthermore, MAO-A protein 
levels seem to be regulated/degraded by UPS in certain regions of the brain (120). Also, it is known 
that protein degradation systems activity, such as UPS, decline with aging. In this way, the increase 
of this protein in aggregates from aged hearts may also suggest an impairment of protein 
degradation via UPS, which cause MAO-A aggregation. Therefore, more studies are needed in 
order to characterize the role of MAO-A in mechanisms underlying cardiac aging, and investigate 
this protein as potential target for the treatment of age-associated cardiovascular diseases. 
Proteins related to contractile function, such as myosin-6 (α-myosin heavy chain), myosin-
7 (β-myosin heavy chain) and myosin light chain 3, were also increased in protein aggregates from 
Aged hearts. Myosin, exist as two heavy chains and four light chains, exhibiting a pivotal role in 
the regulation of cardiac contraction. Correct myosin folding and assembly are essential for the 
maintenance of sarcomere structure, and thereby crucial for its proper function (121). These 
processes require multiple factors, including HSP70 and HSP90 chaperones (122). However, 
aging can interfere with protein folding and refolding as well as with protein degradation systems, 
resulting in the aggregation of unfolded or misfolded proteins (18, 41). In fact, a decline in the 
induction of several chaperones and proteasome activity, which is involved in myosin degradation 
(123), during aging has been reported (64, 65, 67-69). Thus, the greater amount of myosin in 
aggregates from aged hearts may suggest a dysfunction of these proteins, possibly due to the 
folding or degradation impairment, that can contribute to the decreased contractility during cardiac 
aging. 
As mentioned before, chaperones are essential for proteins to acquire their native structure, 
by assisting protein folding, and therefore they have a crucial role in preventing protein 
aggregation. Chaperonin containing TCP1 complex (CCT), also known as the TCP1 ring complex 
(TRiC), is responsible for the folding of approximately 10% of proteins (4, 45). One of those 
proteins is actin, whose correct folding and prevention of aggregation are essential for the 
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formation of thin filaments, contributing to proper function of the sarcomere (124). T-complex 
protein 1 subunit alpha, a molecular chaperone that is a member of TRiC chaperonin, showed to be 
increased in aggregates from aged hearts. Thus, we hypothesized that aggregation of this 
chaperonin may suggest its dysfunction in aging with effects in myofilamentary proteins folding, 
that can underlie cardiac contractility impairment observed in aging. Interestingly, TRiC 
chaperonin seems to be important to restrain the toxic aggregates accumulation in Huntington’s 
disease, suggesting a protective role of this complex, at least in brain cells (125). Therefore, TRiC 
can be a new target for future studies, to elucidate its role in cardiac aggregates suppression and its 
implication in myofilamentary proteins function during aging. Moreover, cardiomyocytes 
hypertrophy, accompanied by increased myofilamentary density, is naturally associated to aging 
and may contribute to the accumulation of important structural myofilamentary proteins, such as 
myosin, in aggregates from Aged rats (126). 
Cathepsin D is another protein that was increased in aged hearts. This protein is the main 
aspartic protease responsible for protein degradation within lysosomes. Any defects in lysosomes, 
and consequently, autophagy machinery lead to several diseases, including neurodegenerative and 
aging-related diseases, as a result of protein misfolded accumulation (127, 128). Wu et al. showed 
that cathepsin D deficiency in mice hearts caused impairment of myocardial autophagosome 
removal, evidencing its role in cardiac autophagic flux. Also, the lack of this protein promotes the 
development of restrictive cardiomyopathy (128). Furthermore, it has been reported that cathepsin 
D is the main lysosomal enzyme involved in α-synuclein degradation, implicated in Parkinson's 
disease pathogenesis, and therefore protects against α-synuclein aggregates toxicity (127). Thus, up 
regulation of cathepsin D in aggregates from aged hearts may indicate dysfunctional protein-
clearance machinery. Proteolytic systems activities, namely autophagy, are known to decrease 
during aging, so aggregation of this protein can be one of the contributors to this decline. All these 
findings make cathepsin D an interesting target for further studies. 
Major vault protein (MVP) is the major component of the vault particle, whose functions 
and regulation are not well elucidated, although it appears to be involved in multi-drug resistance. 
This protein also seems to have an important role in cell survival, possibly mediated by post-
translational modifications in MVP, which promote an inhibition of autophagy-mediated cell death 
(129). The higher abundance of aggregated MVP in aged hearts may possibly be implicated in 
increase of cell death during aging. Since the functions and regulatory mechanisms of MVP are not 
fully understood, this protein may represent a potential new target for research in cardiovascular 
pathophysiology.  
Cardiac aging is accompanied by an increase in fibrosis (collagen content), one of the 
major contributors to progressive increase in ventricular stiffness and impaired diastolic function 
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(130). Lumican, a protein that binds collagen and facilitates collagen assembly, was markedly 
increased in Aged aggregates hearts. Previous work demonstrated that the lack of lumican 
contributes to fibrosis, showing the protective role of this protein in pathogenesis of cardiac 
fibrosis, and evidencing its potential role as novel target for cardiac fibrosis therapy (131). Thus, 
the aggregation of lumican may contribute to the increase in fibrosis observed in aged hearts (130). 
Further studies are required to infer about the implication of lumican aggregation during cardiac 
aging.  
The correct functioning of the cells depends on effective proteostasis. Decline in 
proteostasis mechanisms led to protein misfolding and aggregation, which in turn can cause a broad 
range of diseases (1, 6). Indeed, aging per se represents a relevant cardiovascular risk factor. Thus, 
it is expected that age-related impairment of proteostasis in cardiomyocytes play a role in the 
development of several cardiovascular diseases (3, 18, 63). In fact, DisGeNET analysis revealed 
that several proteins exclusively identified in aggregates from Aged hearts are involved in many 
diseases, namely in cardiovascular and neurological diseases. For example, α-2 macroglobulin is 
associated with Alzheimer’s disease, showing a key role in the inhibition of amyloid formation 
(132). This finding may suggest a common feature/link between protein aggregation in the brain 
and in the heart during aging. Several other proteins, such as transcription activator BRG1, vascular 
endothelial growth factor receptor 1, heat shock related 70kDa protein 2 and proteasome subunit 
beta type-5 are associated with several cardiovascular diseases, like myocardial infarction, 
coronary heart disease and myocardial ischemia. Thus, aggregation of these proteins during normal 
aging process may contribute to the pathophysiology of various cardiovascular diseases.  
 
 
 
 
Cardiovascular impact of Doxo-induced cardiotoxicity in protein aggregation 
  
Cardiotoxicity is capable to induce changes in proteome of adult cardiomyocytes, namely 
in proteins involved in apoptosis, energy metabolism, stress response and different signaling 
pathways (22). In addition, Doxo also promotes modifications in components of protein quality 
control, being associated with proteostasis impairment and protein aggregation (48, 85, 90). 
Patterns of bands of protein aggregates-enriched fractions were similar between Control and Doxo-
treated rabbits. Also, no differences were observed in bands intensities of the gel and in the 
percentage of protein aggregates-enriched fractions between the two groups (supplement B). It 
would be expected that Doxo-treated animals will have higher amounts of protein aggregates in 
comparison to Controls, since its described effects on a variety of different proteins 
modifications/dysfunction, including the ones regulating proteostasis. This unexpected result can 
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be due to the fact that these animals do not yet presented the phenotype typically associated to 
Doxo-induced cardiotoxicity, namely LV dilation, reduced ejection fraction (EF) and contractile 
dysfunction (133). In fact, echocardiographic evaluation showed that Doxo-treated animals, 
comparing to the control animals, presented concentric hypertrophic hearts with preserved EF, 
suggesting that these animals are in an early stage of Doxo-induced cardiotoxicity, and 
consequently, the proteostasis is not yet compromised (data not shown). We believe that the fact 
that cardiac functional evaluation and also tissue collection were carried out 1 week after Doxo 
terminus injection was not sufficient to observe the chronic cardiotoxicity molecular effects 
induced by Doxo. However, there are already changes at the cellular level, including higher amount 
of fibrosis and cardiomyocytes hypertrophy (data not shown). 
Despite the similarity between SDS-PAGE profile and amount of protein aggregates in 
both groups, differences may reside in protein content. GeLC-MS/MS analysis provides the 
identification of distinct proteins in both groups. 20 and 13 proteins were exclusively identified in 
Control and Doxo hearts, respectively, which suggests that Doxo may have specific effects on 
particular proteins that can promote its cardiotoxicity. GRAVY analysis of aggregated proteins 
from Control and Doxo hearts revealed no differences between the two groups, being generally 
more hydrophilic. This finding corroborates our hypothesis that protein aggregation pattern may be 
different in cardiac tissue, when compared to nervous tissue, since in neurodegenerative diseases 
proteins prone to aggregation are more hydrophobic (102). 
ClueGO analysis provided a general view over the main biological processes associated 
with proteins found in LV from both Control and Doxo-treated rabbits. Most of the biological 
processes presented in the ClueGO network are equally shared by the two groups, observed by the 
equivalent percentage of green (Control group) and red (Doxo group) parts in several nodes. This 
outcome would be expected since about 89% of aggregate proteome is common to both groups. 
However, there were some biological processes specific for each group, such as ADP metabolic 
process in Control group and regulation of cardiac contraction in Doxo group. The clearance of 
protein aggregates is mainly done by autophagy. Autophagy occurs at low basal levels in cells to 
perform homeostatic functions such as protein and organelle turnover (9). Therefore, the presence 
of aggregates-enriched fractions in Control group may represent a process that is continuously 
formed under normal conditions and removed by basal autophagy. On the other hand, biological 
processes like muscle contraction and regulation of heart contraction are representative of the Doxo 
group. As mentioned before, cardiac muscle contraction is highly dependent of Ca
2+
 signaling and 
handling (114). In fact, Doxo is known to cause cardiotoxicity by several mechanisms, including 
disruption of Ca
2+
 homeostasis in cardiomyocytes, and consequently, affecting the conduction 
system and contractile function of the heart (23). The pro-arrhythmic effect of Doxo was observed 
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in isolated cardiomyocytes (21). In addition, studies reported that Doxo is capable of induce 
changes in Ca
2+
 channels present in SR, such as SERCA2a and RyR (134). RyR, SR 
transmembrane Ca
2+
 channels, are responsible for the release of Ca
2+
 from SR into cytosol, 
allowing the activation of contractile proteins and heart contraction (134). Disturbed RyR 
activity/function is implicated in several cardiac diseases, such as HF (135). Interestingly, the type 
3 ryanodine receptor (RyR3) was exclusively aggregated on Doxo-treated rabbits, and was the only 
differentiating protein that made regulation of heart contraction biological process representative of 
the Doxo group. This result suggests that Doxo may have specific effects on RyR3, compromising 
its function, and consequently, Ca
2+
 handling and heart contraction. Despite the lack of studies 
showing an association between Doxo-induced cardiotoxicity and RyR3, evidences report that this 
drug can bind directly to type 2 ryanodine receptor (RyR2) (136), another isoform of RyR 
receptors, and alter its activity in cardiomyocytes (134). Moreover, Masumiya et al. demonstrated 
that RyR3 is mainly detected in SA-node and right atrium, whereas RyR2 is expressed in various 
regions of the heart, suggesting that RyR3 may have a unique role in rhythm generation and 
conduction. Therefore, RyR3 protein may be a new target for further studies aiming to understand 
its role in Doxo-induced cardiotoxicity mechanisms. Nevertheless, more studies are needed to confirm 
this hypothesis. The presence of proteins within aggregates-enriched fractions from Doxo-treated 
rabbits involved in cardiac conduction may suggest that Doxo promotes loss of function of these 
proteins, and therefore, changes in conduction system.  
Finally, differential protein analysis of aggregates revealed that only one protein, histidine-
rich glycoprotein (HRG), is markedly increased in Doxo-treated samples. Histidine-rich 
glycoprotein is a multidomain plasma glycoprotein composed by 6 distinct domains, consisting of 2 
N-terminal domains (N1 and N2), 2 proline-rich regions (PRR1 and PRR2) that flank a histidine-
rich region (HRR), and a C-terminal domain. HRG protein binds to a variety of targets, regulating 
several biological processes, such as immune complex, cell adhesion, coagulation and fibrinolysis 
(137, 138). This protein has been also implicated in the regulation of angiogenesis, the formation of 
new blood vessels from pre-existing vessels, in both pro and antiangiogenic manner. The 
antiangiogenic activity has been attributed to HRR/PRR fragment, which is proteolytically released 
from the HRG protein (137, 139). Despite the lack of studies showing a relation between HRG or 
HRR/PRR fragment and Doxo, it is known that this drug can promote changes in angiogenesis, 
namely have an antiangiogenic effect in tumor cells (140). So, it would be conceivable that 
treatment with this drug may have a similar effect on cardiomyocytes. Since HRG fragment was 
markedly increased in Doxo-treated hearts, a hypothesis to explain this finding is that Doxo 
antiangiogenic effect might be related to proteolysis of HRR/PRR fragment from HRG protein. 
However, since Doxo-treated rabbits present an early phenotype of Doxo-induced cardiotoxicity, 
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the aggregation of this fragment could be seen as a cell´s protective response, to prevent 
antiangiogenic effect of this fragment by eliminating/removing it through aggregation. Therefore, 
more studies will be necessary to clarify the effect of Doxo on HRG protein and its impact on 
Doxo-induced cardiotoxicity. 
DisGeNET analysis revealed that proteins exclusively aggregated in Doxo-treated hearts 
were related to cardiovascular diseases, namely interleukin-1 (IL-1) alpha, which was associated 
with myocardial ischemia and cardiomyopathies. In fact, IL-1 family proteins appear to play a 
critical role in the pathogenesis of several heart diseases (141). IL-1 alpha is a pro-inflammatory 
cytokine activated after tissue injury (142). Furthermore, IL-1 seems to participate in Doxo-induced 
cardiotoxicity, once the use of an IL-1 receptor antagonist led to a reduction in heart damage 
caused by Doxo (143). However, since our Doxo-treated animals are in an early stage of Doxo-
induced cardiotoxicity, the specific effects of Doxo in the aggregation of this protein may be 
associated with a protective response to prevent deleterious effects of IL-1 in the heart. Beyond 
that, integrin beta was also identified in DisGeNET network, being related with cardiovascular 
diseases and HF. It is recognized that integrins display a physiological and cardioprotective 
function in cardiomyocytes. The β1D integrin was observed to be down-regulated after myocardial 
infarction (144). Regarding this, the presence of integrin beta in aggregates of Doxo-treated rabbits 
may be explained by its ineffective protective function in the heart, probably due to changes in its 
expression and function. 
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6. CONCLUSIONS AND FUTURE PERSPECTIVES 
Protein misfolding and aggregation have been involved in the pathogenesis of several 
neurodegenerative diseases. We believe that impairment in proteostasis may also contribute to the 
development of cardiovascular diseases. Based on this proteomic study, we demonstrate that both 
aging and Doxo treatment can lead to the formation of protein aggregates in the heart tissue. 
Although levels of protein aggregates-enriched fractions did not differ significantly between Young 
and Aged groups, neither between Control and Doxo groups, distinct proteins were present in those 
aggregates shown significant changes in proteostasis in cardiac aging and in cardiotoxic conditions. 
Among these proteins, the most relevant biological processes observed were related to cardiac 
structure and function, Ca
2+
 homeostasis and autophagy. Therefore, our results open a new field of 
research into the role of protein aggregation in aging and in cardiotoxicity conditions. Next step, 
will be the validation of GeLC-MS/MS results. Also, further research about the proteins 
differentially expressed in aggregates of each group will be important to understand which 
underlying mechanisms impact cardiac aging and cardiotoxicity, and subsequently, its potential as 
novel targets for each of these conditions. 
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8. SUPPLEMENTARY DATA 
 
8.1) Supplement A: Optical density in aging animal model 
   
   
 
 
Figure 28: Optical density (in arbitrary units) comparison of the bands with estimated molecular weight of 240, 125, 95, 
55, 45, 35 and 30 kDa between Young and Aged groups. No differences were observed [1) p=0.0870; 2) p=0.4687; 3) 
p=0.5185; 4) p=0.4013; 5) p=0.1504; 6) p=0.0972; 7) p=0.1273]. Values are represented by mean ± SEM. n=5 in each 
group. 
 
 
8.2) Supplement B: Optical density in Doxo-induced cardiotoxicity animal model 
   
   
Figure 29: Optical density (in arbitrary units) comparison of the bands with estimated molecular weight of 200, 120, 73, 
60, 47 and 35 kDa between Controls and Doxo groups. No differences were observed [1) p=0.5769; 2) p=0.8421; 3) 
p=0.9741; 4) p=0.7085; 5) p=0.9674; 6) p=0.8893]. Values are represented by mean ± SEM. n=5 in each group. 
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8.3) Supplement C: Cohen’s d magnitude for proteins identified in aging animal model 
 
 
Figure 30: Representation of 95% confidence intervals of Cohen’s d magnitude for each protein identified in all Young and Aged 
groups, simultaneously. Proteins with confidence intervals positives are increased in Aged group. Proteins with confidence 
intervals negatives are increased in Young group. 
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8.4) Supplement D: Cohen’s d magnitude for proteins identified in Doxo-induced 
cardiotoxicity animal model 
 
 
 
 
Figure 31: Representation of 95% confidence intervals of Cohen’s d magnitude for each protein identified in all Control 
and Doxo groups, simultaneously. Proteins with confidence intervals positives are increased in Doxo group. Proteins with 
confidence intervals negatives are increased in Control group. 
